

# Subject Index

## A

**ACANTHOSIS NIGRICANS**

and antibodies against insulin receptor, 149

**ACARBOSE**

and carbohydrate absorption in man, 951-954

**ACETALDEHYDE**

and insulin and glucagon secretion in perfused rat pancreas, 705-708

**ACETATE**

and insulin and glucagon secretion in perfused rat pancreas, 705-708

**ACETAZOLAMIDE**

and furosemide  
and renal insulin uptake, 930-933

**ACETOACETATE**

renal clearance of, in diabetic ketoacidosis, 510-517

**ACETONE**

renal clearance of  
in diabetic ketoacidosis, 510-517

**ACETYLCHOLINE**

and electrical activity in perfused isolated mouse islets of Langerhans  
glucose effects compared with, 558-561

**N-ACETYLGUCOSAMINIDASE**

in diabetic and normal serum, 115-117

**ACID**

hyaluronic  
in glycosaminoglycans from diabetic and normal Chinese hamster kidney cells, 393-395  
arachidonic  
platelet metabolism in diabetics and, \*44-47  
13-azaprostanic  
and inhibition of arachidonic-acid-induced platelet aggregation in diabetics and nondiabetics, \*46-47  
organic  
during recovery phase of diabetic ketoacidosis, 310-313

**ACID-BASE BALANCE**

and ketone bodies, 517

**ACID-ETHANOL EXTRACTION**

and insulin content in insects and annelids, 70-75

**ACIDOSIS, HYPERCHLOREMIC**

in diabetes, 785-786

**ACROGIGANTESMIA**

and insulin binding by erythrocytes and monocytes, 896-901

**ACTH**

plasma cortisol response in hyperkalemic diabetics, 338

**ADENINE NUCLEOTIDES**

in erythrocytes from diabetics with ketoacidosis  
insulin therapy and, 346-352

**ADENOMAS**

from rats treated with nicotinamide and streptozotocin  
insulin release in vitro from, 302-308

**ADENOSINE TRIPHOSPHATE**

release from blood platelets after incubation with soluble immune complexes from diabetic sera, 575-578

**ADIPOCYTES**

isolated rat  
insulin binding studies of, 196-201  
insulin-induced receptor loss and internalization in, 746-752  
prostacyclin production, 163-166  
lipogenesis  
immunoglobulin G stimulation of, 1068-1071  
from obese rodents  
insulin resistance studies of, 151  
size  
serum insulin and, 19

**ADIPOSE TISSUE. See also Adipocytes**

rat  
effects of streptozotocin diabetes and insulin on cyclic AMP phosphodiesterase and protein activator in, 372-375

**ADRENAL MEDULLA**

impaired activation during insulin-induced hypoglycemia in diabetics with autonomic neuropathy, 626, 632

**B-ADRENERGIC BLOCKADE**

glucose recovery during, 261-263

**α-ADRENERGIC RECEPTORS**

at pancreatic islet cells, 172-174

**β-ADRENERGIC RECEPTORS**

in rat pancreatic islet cells, 172-174

**AGE**

and blood platelet aggregation in diabetics, 488  
and capillaries of skeletal muscle in diabetics, 328  
and cardiovascular disease mortality in normoglycemics, borderline diabetics, and diabetics, \*50-52  
of diabetes onset

by race and sex in Allegheny County Insulin-Dependent Diabetes Mellitus Registry, 280, 281-283  
of diabetic and nondiabetic Pima Indians and Caucasians

in plasma protein excretion study, 658  
and diabetogenic effects of streptozotocin in mice, 718-722  
and hyperinsulinism and obesity, 14-18  
of hypoglycemia patients in glucose tolerance tests and mixed meals study, 466

in insulin resistant non-insulin-dependent diabetics study, 991

and proinsulin and insulin secretion in isolated rat islets, 77-82

in rural-urban diabetes prevalence study in Polynesians, 47, 48, 49  
and serum glycosidase activity in diabetics and normals, 115-117

**ALBUMIN**

in dermal capillary basement membrane  
in insulin-dependent diabetics, 275-278

in kidney basement membranes and diabetic nephropathy, other kidney diseases, and normal kidney, 843-845

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88

April, 271-365

July, 539-620

October, 797-889

February, 89-174

May, 367-458

August, 621-704

November, 891-982

March, 175-270

June, 459-538

September, 705-796

Supplement 2, 1-110

December, 983-1113

\* This index covers all reading matter in Volume 30 of *DIABETES* except the abstracts of papers presented at the 41st Annual Meeting of the American Diabetes Association. Entries marked with an asterisk indicate material that appeared in Supplement 2, Proceedings of a Conference on Diabetes and Atherosclerosis.

- selective extravascular escape into cerebral cortex of diabetic rat, 500-503
- ALBUMINURIA**  
response to exercise and continuous subcutaneous insulin infusion in insulin-dependent diabetic men, 818-822
- ALCOHOL FLUSH**  
chlorpropamide-induced plasma acetaldehyde as indicator of, 788-790
- ALDOHEXOSES**  
intestinal absorption in streptozotocin-diabetic rats, 569
- ALDOSE REDUCTASE INHIBITORS.** See *Arestatin*
- ALDOSTERONE**  
deficiency and glucose-induced hyperkalemia, 335-339
- ALLOGRAFTS**  
rejection and passenger leucocytes, 242-246
- ALLOXAN**  
diabetogenic effects in mice age and, 719 and inhibition of islet superoxide dismutase, 235-240
- ALLOXAN DIABETES**  
in dogs hypersomatostatinemia of insulin deficiency and high plasma free fatty acid levels and, 358-360 and effect of islet-activating protein in dogs, 430-434  
in rabbits atherosclerosis incidence studies in, \*55 and energy metabolism in peripheral nerve axons and Schwann cells, 967-974 and rat hepatic fructose 2,6-bisphosphate levels, 1062-1064  
in rats coagulation studies in, \*36-37 and intestinal glucose uptake, 247-255
- ARRESTATIN**  
and diabetic peripheral neuropathy, 459-463 and polyol levels in rats, 459
- AMERICAN DIABETES ASSOCIATION**  
Annual Meetings forty-first, 5, xx; 365, 756, 796
- Feasibility Grant Program, 795  
Lilly Award Nominations, 795  
**Necrology**, 3, 1x  
New Members, 2, xiv; 5, xx; 8, xi; 9, v; 86, 538, 795, 1076  
News of Affiliate Associations, 365, 1076  
Organization Section, 2, xiv; 3, ix; 5, xx; 8, xi; 9, v; 86, 365, 538, 795-796, 1076  
Research and Development Award, 795 applications, 86  
Research Grants, 86, 1076  
Reviewers of Manuscripts, 87-88
- AMINO ACIDS**  
dicarboxylic prevention of insulin aggregation by, 83-85 release from muscle to liver and hypoglycemia in pregnancy, 549 transport in fibroblasts from maturity-onset diabetics and unaffected family members, 944
- AMYLASE**  
secretion in rat pancreas insulin and insulin secretagogues and activation of, 396-401
- ANALGESICS**  
in clinical trial of aldose reductase inhibition in diabetic neuropathy, 460-463
- ANGIOGRAPHY**  
and elevated insulin responses to oral glucose in ischemic heart disease, \*54
- ANGIOTENSIN II**  
infusion in hyperkalemic diabetics, 337-338
- ANGIOTENSIN-CONVERTING ENZYME**  
in endothelial cells of large and small vessels, \*25
- ANILINE**  
and removal of labile glycohemoglobin in hemoglobin A<sub>s</sub> assay, 700-701
- ANION GAP**  
unmeasured in diabetic ketoacidosis, 781-785
- ANNELIDS**  
insulin content, 70-75
- ANOXIA**  
effects on phosphorylase activity and glucose metabolism by skeletal muscle of genetically obese-diabetic mice, 214-215
- ANTIBODIES**  
against insulin receptor, 149 and glucose uptake by cultured human fibroblasts, 523-528  
antithyroid and insulin-dependent diabetes and autoimmune thyroid disease, 1060  
to insulin and insulin action studies in diabetics, 652, 654 and insulin resistance, new insulin analogues and, 519-522 and <sup>125</sup>I-insulin, 5  
to insulin, in sera from diabetic patients and soluble immune complexes effect on platelet aggregation and ATP release, 575-578  
islet cell induced in mice, 30-38 islet-cell complement-fixing from diabetics, insulin release and, 1051-1056  
islet-cell-specific and insulin release, 231-234 lymphocytotoxic and histocompatibility antigens in juvenile-onset diabetics, 26-29 monoclonal of lymphocyte hybrid cell lines reaction with rat islet cell membrane antigens, 226-230  
to nucleic acids in insulin-dependent diabetics and unaffected relatives, 873-874
- ANTIGEN-ANTIBODY COMPLEXES**  
and vascular injury, \*2 response to pneumococcal immunization in diabetics and normals, 119-121
- ANTIGENS.** See also Histocompatibility antigens; HLA-DR4 antigens factor VIII in endothelial cells of large and small blood vessels, \*25 of rat islet cell membrane production of monoclonal antibodies reacting with, 226-230
- ANTILYMPHOCYTE SERUM THERAPY**  
and blood donor-specific pretreatment pancreatic islet allograft survival in rats and, 947-950
- ANTISERUM**  
anti-platelet and blocking of atherosclerosis, \*3 and immunologic activity of synthetic insulins, 265-266  
to insulin and wound healing in mice, 407-410 specificity

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88	April, 271-365	July, 539-620	October, 797-889
February, 89-174	May, 367-458	August, 621-704	November, 891-982
March, 175-270	June, 459-538	September, 705-796	Supplement 2, 1-110 December, 983-1113

- in radioimmunoassay and affinity chromatography of somatostatin-like activity, 472
- AORTA**  
chicken  
insulin-induced lesions of, \*55  
rabbit  
comparison of two types of reaction to arterial wall injury in, \*11-12  
and endothelial injury and atherogenesis, \*2-3  
mechanical injury and formation of atherosclerotic lesions in, \*8-9
- APOC-III**  
diet and degree of sialylation of, 530-533
- APOLIPOPROTEINS**  
ApoC-III  
diet and degree of sialylation of, 530-533  
and high-density lipoprotein metabolism in insulin-dependent diabetes, \*84-85
- APOPROTEINS**  
and lipoprotein metabolism in atherosclerosis, \*60-65, \*83
- ARACHIDONIC ACID**  
and atherogenesis, \*3  
platelet metabolism of, in diabetics, \*44-47
- ARGININE**  
high doses in neonatal rat model for non-insulin-dependent diabetes  
insulin and glucagon responses to, 591-592, 594  
-loading tests  
and effect of islet-activating protein in normal dogs, 431-432, 433  
-stimulated insulin release in triphenyltin fluoride-treated rabbits, 1016-1017  
vincristine and, 539-544
- ARTERIES**  
collagen and fibronectin  
and diabetic serum and growth hormone, \*16  
coronary  
in acute myocardial infarction, \*39  
from cholesterol-fed miniature swine, \*60, \*61  
cultured monkey cells  
insulin effects on, \*55-56  
and endothelial injury, \*2-4  
immunological injury to and atherosclerosis, \*9  
injury  
atherogenesis and, \*8-12
- and herpesvirus-induced atherosclerosis in chickens, \*30-31  
lipid metabolism  
in streptozotocin-diabetic rats, \*55  
stiffening in diabetics, \*101
- ARTIFICIAL PANCREAS.** See also Bioartificial pancreas; Insulin infusion systems  
in insulin-dependent diabetics  
correlation between dietary carbohydrate and insulin delivery by, 101-105
- ASPARTIC ACID**  
and insulin aggregation, 83-85
- ASPIRIN**  
and blood platelet aggregation in diabetics, 488
- ATHEROSCLEROSIS**  
animal models of, \*60-61  
and arterial wall metabolism, \*5  
and comparison of two types of reaction to arterial wall injury, \*11-12  
in diabetes  
and blood viscosity elevation, \*102  
distribution of atherosclerotic plaques in, \*99  
and endothelium as barrier, \*100-101  
and fluid phase of coagulation, \*33-38  
and impaired glucose tolerance, \*58-59  
lipoproteins and, \*4-5  
physical factors in development of, \*97-103  
and endothelial injury, \*2-4, \*6, \*10-11  
effects of risk factors on, \*39-42  
and release from contact inhibition, \*21  
triglyceride-rich lipoproteins and, \*19-22  
environmental determinants, \*50  
and foam cells in atheroma, \*3  
herpesvirus-induced  
in chickens, \*29-31  
and high-density lipoprotein composition in insulin-dependent diabetics, 132, 136-137  
hyperglycemia as risk factor in, \*2, \*49-53  
and hyperinsulinemia, \*5  
and immunologic injury, \*9  
induced by intimal injury  
regression of, \*10  
and ischemic complications in diabetics, \*49-50  
lipoprotein metabolism in, \*60-65  
and mechanical injury to aortic wall, \*8-9  
antiplatelet serum prevention of, \*9
- mortality in diabetics and nondiabetics \*1  
noncoronary  
in diabetics, \*49-50  
and plasma lipoprotein abnormalities, \*82  
process of, \*1  
racial differences in incidence of, \*1  
and responses of arterial wall to endothelial injury, \*8-12  
role of arterial injury in pathogenesis of, \*18  
role of insulin  
in diabetics and nondiabetics, \*54-57  
shear stress model of, \*97-103, \*105  
and synergy of arterial injury and hypercholesterolemia, \*9  
types of lesions in humans, \*12  
wound-repair model of, \*39-42
- ATP.** See Adenosine triphosphate
- ATPase**  
sodium, potassium-, and effect of sucrose feeding on obese and normal mice, 975-978
- AUTOANTIBODIES**  
against insulin and somatomedin-C receptors, 979-981  
against insulin receptor  
molecular basis of interaction, 354-357
- AUTOGRAFTS**  
of islet cells in pancreatectomized dogs, 456-458
- AUTOIMMUNE DISEASE**  
and diabetes and lymphocytic thyroiditis in rats, 1058-1060
- AUTORADIOGRAPHY**  
of human mononuclear leukocytes, 128, 130
- 13-AZAPROSTANOIC ACID**  
and arachidonic acid-induced platelet aggregation in diabetics and nondiabetics, \*46-47

**B**

- BASEMENT MEMBRANE**  
dermal capillary, in insulin-dependent diabetics  
albumin deposition in, 275-278  
kidney  
albumin concentrations in diabetes, 843-845  
rat glomerular

January, 1-88  
February, 89-174  
March, 175-270

DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE  
April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

- nonenzymatic glycosylation of, 367–370  
thickening  
in skeletal muscle capillaries of diabetics, 326–333
- BICARBONATE**  
balance  
during recovery phase of diabetic ketoacidosis, 310–313
- BIOARTIFICIAL PANCREAS**  
in streptozotocin-diabetic rats, 296–301
- BIOSTATOR**  
in insulin action evaluation studies in diabetics, 650–655
- BLOOD**  
coagulation  
intrinsic and extrinsic pathway for, \*34–35  
coagulation, fluid phase  
and atherosclerosis of diabetes, \*33–38  
donor-specific pretreatment  
and pancreatic islet allograft survival in rats, 947–950  
erythrocytes  
insulin receptors in sheep, maturation and, 411–414  
measurement of irreversibly glycosylated hemoglobin in, 607–612  
erythrocytes metabolism  
during diabetic ketoacidosis and recovery phase, 346–352  
erythrocytes and monocytes  
insulin binding in normal and disease states, 896–901  
flow  
endothelial responses to, atherogenesis and, \*99–100  
hemoglobin A<sub>1</sub>, assays  
chemical means for removing labile glycohemoglobin in, 700–701  
hydrogen ion concentration  
in metabolic acidosis, 781–782  
monocytes  
insulin binding studies, 196–201  
mononuclear leukocytes in humans with somatostatin and glucagon receptors, 127–131  
pH and diabetic ketoacidosis treatment, 311  
platelets, see Blood platelets  
samples  
in clinical trial of aldose reductase inhibitor in diabetic neuropathy, 460  
in continuous central venous insulin infusion study, 711  
in gastric somatostatin study in streptozotocin-diabetic rats, 188  
in glucose utilization and exercise and insulin study, 984  
in glycogenolysis and gluconeogenesis study in conscious dog, 181  
in immunoglobulin G stimulation of adipocyte lipogenesis study, 1068–1069  
ultrafiltrate  
rat islets perfused with, in bioartificial pancreas, 296–301  
viscosity elevation in diabetic atherogenesis and, \*102
- BLOOD-BRAIN BARRIER**  
insulin receptor  
insulin binding to, 757–761
- BLOOD GLUCOSE**  
control  
and fibrinogen survival, \*36  
and nerve function, 459  
and platelet survival in diabetics, 486–489  
and pubertal stage, effects on somatomedin C in insulin-dependent diabetic children, 868–871  
in diabetic and normal mice, 108  
and evaluation of insulin action in diabetics, 650–655  
and exercise in normals and diabetics, 985  
and hyperglycemia in genetically diabetic mice, 91  
and insulin infusion pump in pregnant diabetics, 891–895  
and islet cell transplantation in streptozotocin-diabetic rats, 481  
levels  
and measurement of irreversibly glycosylated hemoglobin in unstable diabetes, 607–612  
measurement  
and hyperglycemia as risk factor for atherosclerosis, \*90–93  
and mixed meals and dextrose intake in insulin-dependent diabetics  
insulin delivery by artificial pancreas and, 101–105  
and renal hypertrophy in diabetic animals, 485  
response to carbohydrate  
acarbose and, 951–954
- BLOOD PLATELETS**  
activation in diabetics, \*42  
aggregation  
in cerebral and mesenteric microcirculation of mice with genetically determined diabetes, 89–92  
in insulin-dependent diabetics, \*45 and prostacyclin production in diabetics, 935  
aggregation and ATP release  
after incubation with soluble immune complexes purified from diabetic serum, 575–578  
aggregation and coagulation  
and pathogenesis of retinopathy in streptozotocin-diabetic rats, 601–606  
and antiplatelet agents and fibrinogen survival, \*37  
antisera to, and blocking of atherosclerosis, \*3  
arachidonic acid metabolism  
in diabetics, \*44–47  
and atherogenesis, \*3  
-derived growth factor  
atherogenesis and, \*9–10  
in diabetics, atherogenesis and, \*3–4  
\*42  
effects of atherosclerosis risk factors on, \*39–42  
factor 4  
in plasma of coronary artery disease, peripheral artery disease, and diabetic patients, \*33–34  
factors  
and intimal hyperplasia, \*9–10  
and fluid phase of coagulation in diabetic atherosclerosis, \*33–38  
function and turnover  
in hypercholesterolemia and diabetes, \*39  
hyperaggregation in diabetics, factors associated with, 488  
nonadhesion to endothelial cells from large and small vessels, \*26  
survival  
in diabetics, 486–489  
synthesis of prostaglandin endoperoxides  
and vascular disease, \*47
- BLOOD PRESSURE**  
systolic  
and insulin-induced hypoglycemia in diabetics with and without autonomic neuropathy, 630, 631, 632
- BLOOD SUGAR**  
of cold-adapted and control eels, 317–325  
and diabetes gene expression in mice, 1031  
effect on intestinal sugar transport  
structural specificity of, 571–572  
and exercise and insulin therapy, 983–988
- BLOOD VESSELS**  
cerebral and mesenteric  
platelet aggregation studies in genetically diabetic mice, 89–92  
large and small  
comparison of endothelial cells of, \*24–27

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1–88	April, 271–365	July, 539–620	October, 797–889
February, 89–174	May, 367–458	August, 621–704	November, 891–982
March, 175–270	June, 459–538	September, 705–796	Supplement 2, 1–110

**retinal**  
 microthrombus formation in streptozotocin-diabetic rats, 601–606  
 transplantation of isolated islets via portal vein into diabetic mice, 285–290

**BODY**

leg glucose uptake  
 insulin and, 1000–1006

**BODY MASS INDEX**

of insulin-resistant non-insulin-dependent diabetics, 991  
 in rural-urban diabetes prevalence study in Polynesians, 49

**BODY WEIGHT**

at birth  
 of infants of diabetic mothers with insulin infusion pumps during pregnancy, 895  
 in diabetic and normal mice, 107  
 effect of streptozotocin in rats on, 189  
 and expression of mutations at diabetes locus in mice, 1031  
 and gastrointestinal insulinotropic hormones response to oral glucose in normal and gestational-diabetic pregnancy, 504–508  
 and glycosuria in mice, 90  
 in insulin and exercise and glucose utilization study, 983  
 loss  
 rat aorta 6-oxo-prostaglandin F<sub>1α</sub> production and, 937, 938  
 and skeletal muscle morphology and enzyme activities, 19–25

**BONES**

congenital lumbar and sacral malformations in offspring of diabetic rats and diabetic control during organogenesis, 965–969  
 proteoglycans biosynthesis in streptozotocin-diabetic rats, 670–677

**BORDETELLA PERTUSSIS**

islet-activating protein purified from effect on immunoreactive insulin and glucagon secretion in normal, alloxan-treated, and depancreatinized dogs, 430–434

**BOROHYDRIDE REDUCTION**

of proteoglycans from diabetic rat bone and cartilage, 673

**BRAIN**

cerebral cortex of diabetic rat extravasation of plasma proteins into, 500–503

cerebral edema  
 following saline and insulin therapy in streptozotocin-diabetic rats, 762–766  
 insulin binding to isolated microvessels, 757–761

**C****CALCIUM**

deficiency in diabetic rats, 383–384  
 -dependent phosphatidylinositol breakdown and amylase secretion in rat pancreas  
 insulin and insulin secretagogues and, 396–401  
 and glucose-stimulated insulin release and trifluoperazine, 960–966  
 in rat pancreatic islets  
 glucose and, 52–54  
 and somatostatin mechanism of action in pancreatic islet β-cells, 836–841

and veratridine effects on glucagon and insulin secretion, 446–449  
 and vitamin D  
 and insulin secretion, 384–385  
 and zinc-induced inhibition of insulin secretion from rat islets of Langerhans, 342, 343–344

**CALMODULIN**

and glucose-stimulated insulin release and trifluoperazine, 960–966

**CALORIMETRY, INDIRECT**

in exercise and insulin and glucose utilization study, 984, 987  
 and insulin clamp studies, 1002

**CAPILLARIES**

basement membrane width  
 in parents of children with type I diabetes, 475–479  
 from bovine cerebral cortex  
 insulin binding to, 757–761  
 of cold-adapted eels, 317–325  
 density  
 body weight and, 19, 20–21  
 dermal basement membrane  
 albumin deposition in insulin-dependent diabetics, 275–278  
 skeletal muscle  
 in diabetics, pericyte degeneration and basement membrane thickening in, 326–333

**CARBOHYDRATE**

absorption  
 and acarbose, 951–954  
 dietary  
 and degree of sialylation of apoC-III, 530–533

dietary, nature and amount  
 correlation with insulin delivery by artificial pancreas in insulin-dependent diabetics, 101–105

homeostasis  
 zinc and, 341  
 ingestion  
 and postprandial hypoglycemia diagnosis, 996–999  
 intolerance, in type II, non-insulin-dependent diabetics  
 and measurement of *in vivo* insulin resistance, 618  
 metabolism  
 and gastric somatostatin, 188  
 tolerance tests  
 and acarbose effects on carbohydrate absorption, 951–954

**CARBON DIOXIDE**

concentrations in expired air  
 in glucose utilization and exercise study, 984  
 serum levels  
 increase during recovery phase of diabetic ketoacidosis, 310–313

**<sup>14</sup>CARBON DIOXIDE**

conversion of <sup>14</sup>C-glucose into by perfused skeletal muscle of genetically obese-diabetic mice, 211–217

**CARDIOVASCULAR DISEASE. See also**

Atherosclerosis  
 atherosclerotic and high-density lipoprotein composition in insulin-dependent diabetics, 132–137  
 plasma cholesterol as risk factor in, \*76, \*78

**CARDIOVASCULAR SYSTEM**

and hyperglycemia, 222, 224–225

**CARTILAGE**

proteoglycans biosynthesis in streptozotocin-diabetic rats, 670–677

**CASE REPORT**

long-term continuous intraperitoneal insulin infusion system, 1072–1074

**CATECHOLAMINES**

in diabetics with autonomic neuropathy, 626, 632  
 microvessel response to in streptozotocin-diabetic Syrian hamsters, 94–100

**CAUCASIANS**

diabetic and nondiabetic urinary excretion and renal clearance of specific plasma proteins, compared with Pima Indians, 656-662

**CELLS**

cultured rat islet tumor hormones and factors stimulating growth of, 1022-1027

endothelial, see Endothelial cells fibroblasts from maturity-onset diabetics and unaffected relatives insulin binding and action in, 940-945

Friend erythroleukemia alteration of fatty acid composition of, effects on insulin receptors of, 773-779

glucagon immunoreactive of two populations of ratfish islet cells, 192-195

human-mouse hybrids and location of human insulin gene from DNA isolated from, 267-270

mouse lymphocyte hybrid and production of monoclonal antibodies reacting with rat islet cell membrane antigens, 226-230

peritoneal exudate and rejection of islet allografts, 242-246

rabbit aorta myomedial as model for diabetic macroangiopathy, \*14-16

rat spleen and rejection of islet allograft, 289-290

smooth muscle and atherogenesis, \*9-10 function in low oxygen environment, \*41

insulin effects on, \*55-56

insulin effects on lipid metabolism of, \*56-57

proliferation, and atherogenesis pathogenesis, \*18

proliferation in artery intima, \*39

transport and microtubules, 539

**CESIUM CHLORIDE DENSITY GRADIENT CENTRIFUGATION**

in proteoglycans biosynthesis study in diabetic rats, 673, 674, 675

**CHICKENS**

herpesvirus-induced atherosclerosis in, \*28-31

insulin-induced aortic lesions in, \*55

**CHILDREN. See also Juvenile diabetes**

insulin-dependent diabetic

effect of pubertal stage and blood glucose control on plasma somatotropin C in, 868-871

obese, of obese parents, hyperinsulinism studies in, 14-18

**CHINESE HAMSTERS**

diabetic

dicarboxylic amino acids and prevention of insulin aggregation in, 83-85

diabetic and normal glycosaminoglycan from kidneys of, 393-395

**CHLOROQUINE**

in <sup>125</sup>I-insulin binding studies, 598 and renal insulin uptake, 930-933

**CHLORPROPAMIDE ALCOHOL FLUSH**

plasma acetaldehyde increase as indicator of, 788-790

**CHOLESTEROL**

dietary

and lipoprotein metabolism in atherosclerosis, \*60-65

ester and free

in injury-induced lesions in rabbit aorta, \*8-9

in high-density lipoprotein particles diabetes and, \*5

in insulin-dependent diabetics, 132-137

levels

and herpesvirus-induced atherosclerosis in chickens, \*29-31

metabolism

in endothelial cells, \*20

metabolism in diabetics

diet and, \*76-81

synthesis

endothelial cell, \*22

total

in plasma of obese children of obese parents, 15-17

**CHROMATOGRAPHY**

affinity

and radioimmunoassay of somatostatin-like immunoreactivity in human peripheral plasma, 471-474

column

and glycosylated hemoglobin assays, 115

DEAE-cellulose

and collagen assays in arterial wall, \*16

and protein activator of phosphodiesterase assays, 373-375

**gas**

and breath hydrogen levels, in acarbose and carbohydrate absorption study, 952, 953-954

**gel filtration**

of immunoreactive insulin released from adenoma tissues of nicotinamide and streptozotocin-treated rats, 305, 306

of somatostatin-like activity, 472

and hepatic extraction of plasma immunoreactive glucagon components in dogs, 768-771

**liquid**

and removal of labile glycohemoglobin in hemoglobin A<sub>1</sub> assay, 700-701

and measurement of glycosylated hemoglobin, 614

**molecular sieve**

of proteoglycans from diabetic rats, 675-676

**sepharose**

in proteoglycans biosynthesis study, 673

**<sup>51</sup>CHROMIUM**

-labeled platelets

in platelet survival study in diabetics, 486-489

**CHROMOSOMES**

location of human insulin gene on, 267-270

 **$\alpha$ -CHYMOTRYPSIN**

and proteolysis in peripheral nerve myelin in streptozotocin-diabetic and normal rats, 292-294

**CHYMOTRYPTIC CLEAVAGE**

of <sup>125</sup>I-insulin, 2

**CIGARETTE SMOKING. See Smoking****COLCHICINE**

and insulin secretion in man, 1008-1012

**COLLAGEN**

and arterial stiffening in diabetes, \*101

in arterial wall

growth hormone and increase in, \*16 of glomerular basement membrane from diabetic rats

ketamine-linked glucose levels in, 616

**COLLAGENASE**

and isolation of tumors from pancreas of nicotinamide and streptozotocin-treated rats, 302, 303

perfusion of dog pancreatic duct with and preparation of viable islet cells, 455-458

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88

February, 89-174

March, 175-270

April, 271-365

May, 367-458

June, 459-538

July, 539-620

August, 621-704

September, 705-796

October, 797-889

November, 891-982

Supplement 2, 1-110

December, 983-1113

**COLORIMETRY**

and measurement of glycosylated hemoglobin, 614-615

**COMA, HYPOGLYCEMIC**

and mortality, 177

**COMPLEMENT**

$C_3$ , extravasation into cerebral cortex of diabetic rats, 500-503  
-fixing islet cell antibodies in serum from diabetic patients and insulin released from mouse islets incubated with, 1051-1056  
and islet-cell specific antibodies and insulin release from rat pancreatic  $\beta$ -cells, 231-234

**CONCANAVALIN A**

and glucose uptake by cultured human fibroblasts, 523-528

**CONGENITAL MALFORMATIONS**

lumbosacral defects in neonatal rat offspring and diabetic control during organogenesis, 955-959

**COSYNTROPIN**

infusion in hyperkalemic and normokalemic diabetics plasma cortisol and aldosterone and, 337-339

**COWS**

inhibition of superoxide dismutase by diabetogenic drugs, 235-240

**COXSACKIE VIRUS B4**

and HLA antigens in juvenile diabetics and siblings in prospective study, 584-589

**CREATININE**

clearance and aldose reductase inhibition in diabetic neuropathy, 460

**CYCLIC AMP**

and glucose-induced insulin secretion in fetal and neonatal rat pancreas, 60, 62  
in isolated rat islets prostacyclin and 6-keto-prostaglandin  $F_{1\alpha}$  and, 824-827  
liver production of and glucagon stimulation, 185 phosphodiesterase and protein activator of in adipose tissue from insulin-treated streptozotocin-diabetic rats, 372-375  
and somatostatin and insulin secretion from isolated, perfused rat pancreas, 40-44

**CYCLOHEXIMIDE**

-inhibition of protein synthesis and intestinal sugar transport in rats, 572

**CYTOTOXICITY STUDIES**

of lymphocyte tissue, 227

**D****2 DEOXY-D-GLUCOSE**

-induced hyperglycemia and wound healing in mice, 407-410 uptake by cultured human fibroblasts insulin and insulin-like agents and, 523-528

**DEXTROROSE**

ingestion and insulin delivery by artificial pancreas in insulin-dependent diabetics, 101-105

**DIABETES MELLITUS**

and albumin concentrations in kidney basement membranes, 843-845 arterial stiffening in, \*101 and atherogenesis, \*3-4 and atherosclerosis and fluid phase of coagulation, \*33-38 mortality, \*1 and "non-coronary cardiopathy," \*49-50 physical factors in development of, \*97-103 blood clotting assays in, \*35 and blood platelet survival, 486-489 causes of endothelial injury in, \*2 in Chinese hamsters and amino acids effects on insulin aggregation, 83-85 and kidney glycosaminoglycan, 393-395 and cholesterol metabolism diet and, \*76-81 classifications and insulin resistance in type II diabetes, 739-744 and clotting factor levels, \*35-36 and complement-fixing islet cell antibodies incubation of isolated mouse islets with sera from, 1051-1056 control and high-density lipoprotein and cholesterol levels, \*89 and long-term continuous intraperitoneal insulin infusion system, 1073-1074 and measurement of irreversibly glycosylated hemoglobin, 607-612

and decreased bone formation and cartilage and bone proteoglycans biosynthesis abnormalities in diabetic rats, 670-677

diet-treated, maturity onset and brief, irregular oscillations of basal plasma insulin and glucose concentrations, 435-439 duration

arterial calcification and, \*14 urinary excretion and renal clearance of specific plasma proteins and, 656-662

and elevated blood viscosity atherogenesis and, \*102 encephalomyocarditis virus-induced in mice

genetic obesity and, 451-454 endothelial cell studies in, \*41-42 and endothelial injury, \*2-3

and evaluation of insulin action of highly purified beef and pork insulins and conventional insulins, 650-655

and exercise and glucose utilization, insulin and, 983-988

glycosylated hemoglobin structure and synthesis in, 613-616

and heredity and identification of insulin gene, 270 high-density lipoproteins in, \*82-85 and hyperkalemia and renin-angiotensin-aldosterone system, 335-339

and hypertriglyceridemia and atherosclerosis, \*4-5 and impaired wound healing, 407 and inhibitors of coagulation proteases, \*36

insulin-dependent and albumin deposition in dermal capillary basement membrane, 275-278

continuous subcutaneous insulin infusion and correction of exercise-induced microalbuminuria in, 818-822

and correlation between dietary carbohydrate and insulin delivery by artificial pancreas in, 101-105

epidemiologic characteristics of, and prospective study of viral antibody titers and HLA-B locus antigens, 584-589

and erythrocyte and monocyte insulin binding studies, 896-901

high-density lipoprotein composition in, 132-137

and high-density lipoprotein metabolism, \*84-85

incidence in Allegheny County, Pennsylvania, 279-283

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88

April, 271-365

July, 539-620

October, 797-889

February, 89-174

May, 367-458

August, 621-704

November, 891-982

March, 175-270

June, 459-538

September, 705-796

Supplement 2, 1-110

December, 983-1113

with microvascular disease, acetylator phenotypes in, 907-909  
nucleic acid antibodies in, 873-874  
spontaneous in rats, and lymphocytic thyroiditis, 1058-1060  
insulin-dependent, adult-onset pneumococcal immunization in, 119-121  
and insulin metabolism  
and atherosclerosis, \*55  
insulin- and non-insulin-dependent and hypertriglyceridemia, \*66, \*67, \*68-69, \*70, \*71-74  
insulin-resistant and simultaneous inhibition of insulin and somatomedin-C binding to cultured IM-9 lymphocytes from, 979-981  
insulin treated and polymorphonuclear leukocytes-stimulated glucose oxidation and iodination, 256-259  
juvenile-onset long-term study of mortality and vascular complications in, 175-178  
lymphocytotoxic antibodies and histocompatibility antigens in, 26-29  
with and without autonomic neuropathy, and hormonal, metabolic, and cardiovascular responses to insulin-induced hypoglycemia, 626-632  
maternal and immunocytochemical study of pancreatic specimens from infants of, 271-273  
maturity-onset of the young insulin binding and action in fibroblasts from, 940-945  
in mice and influence of H-2 haplotype and sex on expression of, 1029-1034  
and prevention of nephropathy by diet control, 106-111  
and microangiopathy, 93-94, 100  
mild and epinephrine-propranolol infusions for measurement of insulin resistance, cardiac arrhythmias during, 618-620  
mild and severe and plasma glucose, insulin, and C-peptide response to glucagon injection, 685-692  
in new strain of genetically obese-hyperglycemic rat, 1045-1049  
non-insulin-dependent and chlorpropamide alcohol flush, plasma acetaldehyde as indicator of, 788-790  
effects of insulin therapy on insulin resistance in, 739-744  
and glucose utilization during glucose clamp studies, 829-834

and hyperinsulinemia, \*1-2  
and hyperinsulinemia and atherosclerosis, \*5  
and hypertriglyceridemia, \*70  
insulin binding, internalization, and insulin receptor regulation in fibroblasts from, 596-600  
insulin resistance in, 157-160, 990-995  
and insulin resistance study in fibroblasts, 562-566  
islet secretion in new animal model of, 590-594  
and mortality from atherosclerosis, \*1  
and obesity in mice  
and hormone regulation of glucose metabolism, 211-217  
and pathophysiology of metabolic acidosis, 781-786  
platelet arachidonic acid metabolism in, \*44-47  
prevalence in rural and urban Polynesian population of Western Samoa, 45-50  
and renal impairment and defective hydroxylation of phenformin, 644-649  
serum glycosidase activity in, 115-117  
skeletal muscle capillaries and, 326-333  
soluble immune complexes from serum platelet aggregation and ATP release after incubation with, 575-578  
and symptomatic polyneuropathy comparison of clinical course and sequential electrophysiological test results and myo-inositol therapy, 139-147  
Vacor-induced, 235  
and Wistar "BB" rats and T-cell lymphocytopenia, 887-889

**DIET**

and cholesterol metabolism in diabetes, \*76-81  
comparison of oral glucose tolerance tests and mixed meals in hypoglycemic patients, 465-469  
composition in triphenyltin fluoride and hypertriglyceridemia study in rabbits, 1014  
fiber supplements and carbohydrate absorption, 951  
high-carbohydrate in starved alloxan diabetic rats, and hepatic 2,6-bisphosphate levels, 1062-1064  
high-fat-high cholesterol and lipoprotein metabolism in atherosclerosis, \*60-65  
intake of triphenyltin fluoride-treated rabbits, 1015

and juvenile-onset diabetes, 176  
mixed meals and dextrose intake and insulin delivery by artificial pancreas in insulin-dependent diabetics, 101-105  
and plasma lipids and cholesterol, \*88 and plasma removal of very-low-density lipoproteins in insulin-deficient rats, 496-497, 498  
and prevention of diabetic nephropathy in diabetic mice, 106-111  
sucrose overfeeding and Na, K-ATPase-mediated potassium uptake in normal and obese mice, 975-978

**DIHYDROXYACETONE**

and somatostatin release from pancreatic D-cells, 205-207

**I,25 DIHYDROXYVITAMIN D<sub>3</sub>**  
and insulin secretion, 382-385

**DNA.** See also Recombinant DNA methodology  
antibodies to  
in insulin-dependent diabetics and unaffected relatives, 873-874  
of cultured rat pancreatic islets  
myo-inositol inhibition of <sup>3</sup>H-thymidine incorporation into, 622, 623-624  
in fetal and neonatal rat islet of Langerhans  
insulin secretion and, 58-59  
kidney cell content  
in streptozotocin-diabetic rats, 484, 485  
and location of human insulin gene, 267-270  
synthesis  
in cultured monkey aortic smooth muscle cells, insulin effects on, \*55-56

**DOGS**

alloxan diabetic  
hypersomatostatinemia of insulin deficiency and high plasma free fatty acid levels in, 358-360  
effect of digested and undigested gluten on postprandial insulin and glucagon levels in, 362-364  
glucagon and glycogenolysis and gluconeogenesis study in, 180-186  
hepatic extraction of plasma immunoreactive glucagon components in, 767-779  
and hypophosphatemia  
and insulin responses, 384  
inhibition of erythrocyte superoxide dismutase by diabetogenic drugs in, 235-240  
liver glucose production in glucagon deficiency and, 490-494

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

liver secretion of  $\beta$ -very-low-density lipoproteins in, \*63–64  
 normal oxytocin infusion and plasma insulin and glucagon levels and glucose production and uptake in, 112–114  
 normal, alloxan-treated, and depancreasized effect of islet-activating protein on immunoreactive insulin and glucagon secretion in, 430–434  
 normal and vagotomized effect of somatostatin on thoracic duct lymph flow rate and triglyceride levels in, 440–444  
 pancreas D-cell recognition of D-glucose, 203–209 preparation of viable islet cells from, 455–458 protein- and acid-induced splanchnic somatostatin release in insulin and, 735–738 somatostatin-suppression of portal and peripheral insulin concentrations in glucose and changes in, 664–668

**DOPAMINE- $\beta$ -HYDROXYLASE** increased activity in streptozotocin-diabetic rats characterization of, 416–423

**DROSOPHILA MELANOGASTER** insulin content, 70–75

## E

**EARTHWORMS.** See Annelids

**EDEMA**

cerebral and extravascular escape of albumin into cerebral cortex of diabetic rats, 500–503 following fluid and insulin therapy in streptozotocin-diabetic rats, regional localization of, 762–766

**EELS**

cold-adapted hyperglycemia and microangiopathy in, 317–325

**ELECTRICAL ACTIVITY**

of pancreatic islet cell membrane effects of glucose and acetylcholine on, 558–561

**ELECTROCARDIOGRAMS**

abnormalities and glucose intolerance and arterial disease, \*50–52

**ELECTROLYTES**

serum and urinary during recovery phase of diabetic ketoacidosis, 310–313

**ELECTROPHORESIS**

and analysis of glycosaminoglycans from diabetic and normal Chinese hamster kidney cells, 393–395

and measurement of glycosylated hemoglobin, 614, 615

polyacrylamide gel of  $^{125}\text{I}$ -insulin, 2, 3 and superoxide dismutase assays, 236, 239–240

and removal of labile glycohemoglobin in hemoglobin A<sub>1</sub> assay, 700–701

sodium dodecyl sulfate-polyacrylamide gel

in autoantibodies against insulin receptor study, 354–357

and collagen assays in arterial wall, \*16

**ELECTROPHYSIOLOGICAL STUDIES**

of diabetics with symptomatic polyneuropathy compared with clinical course, 139–147

of somatostatin mechanism of action in pancreatic islet  $\beta$ -cells, 836–841

**ENCEPHALOMYOCARDITIS VIRUS**

-induced diabetes in mice effects of genetic obesity on, 451–454

**ENDOCRINE GLANDS**

and lymphocytic thyroiditis in diabetic insulin-treated rats, 1058–1060

**ENDOTHELIAL CELLS**

as barrier atherogenesis in diabetics and, \*100–101

cholesterol metabolism, \*20

contact inhibition in culture, \*20

function in low oxygen environment, \*41

homocystinuria as model of platelet response to injury to, \*40

injury

and risk factors for atherosclerosis, \*39–42

in large and small vessels, \*32

comparison of, \*24–27

features common to, \*25–26

migration of, \*26–27

nutritional requirements, \*26

substratum requirements for growth of, \*26

migration

and wound-repair response, \*40

receptors for triglyceride-rich lipoproteins, \*19–22

**ENDOTHELIUM.** See also Endothelial cells

permeability and wall shear stresses

atherogenesis and, \*101

responses to blood flow

atherogenesis and, \*99–100

**ENVIRONMENTAL FACTORS**

and atherosclerosis in diabetics, \*50, \*58

**ENZYMES**

angiotensin-converting

in endothelial cells of large and small vessels, \*25

electrophoretic analysis of

location of insulin gene and, 267

glycogen synthase and pyruvate dehydrogenase activities

in skeletal muscle of genetically obese-diabetic mice, 216

glycolytic

and glucose metabolism in rat pancreatic islets, 923–928

iodotyronine

metabolism in diabetic rats, 694–698

ornithine decarboxylase

regulation in skeletal muscle from diabetic fed and starved rats, 675–683

in pancreatic islets

glucose metabolism regulation and, 911–921

6-phosphofructo 1-kinase activation assay for fructose 2,6-bisphosphate

in alloxan diabetic rat liver, 1062–1064

serum glycosidic

in diabetics and normals, 115–117

skeletal muscle

and fasting serum insulin and glucose tolerance, 19–25

superoxide dismutase

inhibition by diabetogenic drugs, 235–240

transmitter

retrograde axonal transport in streptozotocin-diabetic rats, 797–802

trypsin and  $\alpha$ -chymotrypsin

and proteolysis in peripheral nerve myelin in streptozotocin diabetic and normal rats, 292–294

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1–88

April, 271–365

July, 539–620

October, 797–889

February, 89–174

May, 367–458

August, 621–704

November, 891–982

March, 175–270

June, 459–538

September, 705–796

Supplement 2, 1–110

December, 983–1113

**EPIDEMIOLOGICAL STUDIES**

of role of abnormal insulin response to oral glucose  
and atherosclerosis in diabetics and nondiabetics, \*54-55

**EPINEPHRINE**

effects on phosphorylase activity and glucose metabolism by skeletal muscle of genetically obese-diabetic mice, 214-215  
propranolol, glucose, and insulin infusions for measurement of insulin resistance in mildly diabetic or hyperlipidemic men  
cardiac arrhythmias during, 618-620  
and recovery from hypoglycemia, 262-263

**EPITHELIAL CELLS.** See also Epithelium  
blockade of lipoprotein interiorization, \*20-21

from large and small vessels  
formation of three-dimensional networks in vitro, \*27

**EPITHELIUM**

ciliary and retinal pigmented  
and glucose transport across ocular barriers of diabetic rats, 903, 905

**ERYTHROCYTES**

incubation in semicarbazide and aniline and removal of labile glycohemoglobin in hemoglobin A<sub>1</sub> assay, 700-701  
insulin binding  
in normal and disease states, 896-901  
insulin receptors  
disappearance during maturation in sheep, 411-414  
metabolism  
during diabetic ketoacidosis, 346-352  
oxygen transport in diabetics  
and arterial injury from hypoxia, \*2

**17 $\beta$ -ESTRADIOL**

and expression of mutations at diabetic locus in male mice, 1036, 1037-1038

**ESTRADIOL BENZOATE**

and skeletal muscle metabolism in rats, 548-550

**ETHANOL**

effects on insulin and glucagon secretion  
in perfused rat pancreas, 705-708

**EUGLYCEMIC GLUCOSE CLAMP TECHNIQUE**

assessment of insulin resistance with insulin suppression test and, 387-392  
and evaluation of insulin action in diabetics, 650-655  
and glucose utilization and clearance study in normal man, 535-537  
and insulin and glucose effects on sympathetic nervous system activity in normal man, 219-225  
and insulin and intravenous glucose disposal study, 1000-1006  
and insulin resistance studies, 151-155 prolonged  
enhanced glucose utilization during, 829-834

**EXERCISE**

and glucose utilization  
in normal and diabetic subjects, insulin and, 983-988  
-induced microalbuminuria  
in insulin-dependent diabetics, correction with continuous subcutaneous insulin infusion, 818-822  
and insulin-dependent diabetics  
blood glucose control and, 822

**EXORPHINS**

and plasma insulin and glucagon levels in dogs, 362-364

**EYES.** See also Retinopathy, diabetic

glucose transport across ocular barriers of, in streptozotocin-diabetic rats, 903-905

**F****FACTOR VIII**

in diabetics, \*35-36

**FAMILY STUDIES**

of insulin binding and action in fibroblasts from patients with maturity-onset diabetes of the young and unaffected relatives, 940-945

siblings of juvenile diabetics  
viral antibody titers and HLA B locus antigens in, 584-589

**FASTING**

in alloxan diabetic rats  
and coagulation studies, \*36-37  
and glucose use and insulin release in rat pancreatic islets, 923-928

**FATS**

dietary  
and lipoprotein metabolism in atherosclerosis, \*60-65

**FATTY ACIDS**

composition of Friend erythroleukemia cells  
effect on insulin receptors of, 773-779  
free  
and exercise in diabetics and normals, 985  
high plasma levels, and hypersomatostatinemia of insulin deficiency, 358-360

**FECAL BILE ACIDS**

and sterol balance techniques  
in cholesterol metabolism studies, \*78-81

**FECAL NEUTRAL STEROIDS**

and sterol balance techniques  
in cholesterol metabolism studies, \*78-81

**FEET**

and peripheral vascular disease in diabetics, \*49-50

**FETUS**

human  
stomach glucagon content, 879-882  
and maternal hyperglycemia, 271, 273  
mouse pancreas  
organ culture conditions and insulin and glucagon secretion, 804-811

rat  
glucose-induced insulin secretion in, 56-62  
rat pancreas  
transplantation into adult diabetic rats, 9-12

**FIBRINOGEN**

in diabetics, \*36  
turnover  
in coagulation studies, \*36-37

**FIBRINOLYTIC SYSTEM**

in diabetes, \*36

**FIBROBLASTS**

cultured human diploid  
effects of insulin and insulin-like agents on glucose transport system of, 523-528  
effect of pH and 3-hydroxybutyrate on insulin binding and action in, 402-405  
and glycosylated low density lipoproteins, 876-877

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88

February, 89-174

March, 175-270

April, 271-365

May, 367-458

June, 459-538

July, 539-620

August, 621-704

September, 705-796

October, 797-889

November, 891-982

Supplement 2, 1-110

December, 983-1113

low-density lipoprotein receptors on, \*60  
and maturity-onset diabetes of the young  
insulin binding and action in, 940–945

**FIBRONECTIN**  
accumulation in arterial wall  
diabetic serum and growth hormone and, \*16  
and atherosclerosis, \*5

**FICOLL-HYPAQUE METHOD**  
and identification of human somatostatin  
and glucagon receptor-bearing human mononuclear leukocytes, 127–131

**FRIEND ERYTHROLEUKEMIA CELLS**  
insulin receptors  
alteration of fatty acid composition on, 773–779

**P-FRUCTOKINASE**  
and regulation of glucose metabolism in rat pancreatic islets, 915, 916

**FRUCTOSE**  
and somatostatin, insulin, and glucagon release, 207–209

**FRUCTOSE 2, 6-BISPHOSPHATE**  
in rat liver  
and alloxan diabetes and starvation and refeeding, 1062–1064

**FUCOSE**  
-labeled protein  
rapid axonal transport in diabetic rats, 797–802

**FUROSEMIDE**  
and acetazolamide  
and renal insulin uptake, 930–933

**G**

**GALACTITOL**  
accumulation in peripheral nerves and lens of diabetic rats, 459

**GALACTOSE**  
and somatostatin, insulin, and glucagon release, 207–209

**β-GALACTOSIDASE**  
in diabetic and normal serum, 115–117

**GAMMA-AMINOBUTYRIC ACID**  
agonists, See Muscimol

**GANGRENE**  
and diabetes, \*49

**GASTRIC EMPTYING**  
in pregnancy  
and reduced gastric inhibitory polypeptide response to oral glucose, 508

**GASTRIC INHIBITORY POLYPEPTIDE**  
response to oral glucose  
in normal and gestational-diabetic pregnancy, 504–508

**GASTROINTESTINAL SYSTEM**  
and carbohydrate absorption  
acarbose and, 951–954  
D-cells  
hyperfunction in streptozotocin-diabetic rats, pancreas transplantation and, 724–726  
gastric somatostatin concentration and secretion  
in streptozotocin-diabetic rats, 188–191  
glucose uptake in diabetic rats, 247–255  
gut glucagon-like immunoreactivity transformation into pancreatic glucagon in piglets, 792–794  
and hyperinsulinemic response to oral glucose and atherosclerosis, \*54  
insulin absorption in rats  
and sodium 5-methoxysalicylate, 1065–1067  
insulinothropic hormones response to glucose  
in normal and gestational-diabetic pregnancy, 504–508  
intraperitoneal long-term continuous insulin-infusion system, 1070–1074  
protein- and acid-induced splanchnic somatostatin release in dogs  
insulin and, 735–738  
small intestine  
reductase activity in diabetic rats, and hypercholesterolemia, \*80–81  
sugar transport  
in streptozotocin-diabetic rats, 568–574  
total duodeno-pancreatectomy and gastrectomy in humans, glucagon immunoreactivity and somatostatin action in, 851–855  
triglyceride secretion in streptozotocin-diabetic rats, \*68

**GEL FILTRATION**  
Sephadex  
and human plasma somatostatin radioimmunoassay, 728–733

**GENES**  
HLA-DR4 antigens  
and capillary basement membrane width in parents in type I juvenile diabetics, 475–479  
mutant in mice  
expression of, H-2 haplotype and sex and, 1029–1034  
and secretion of structurally abnormal insulin molecule, 148  
transfer from Zucker rat to Wistar Kyoto rat  
new genetically obese-hyperglycemic rat bred from, 1045–1049

**GENETICS.** See also Genes; Heredity  
insulin gene location, 267–270  
and lymphocytotoxic antibodies and histocompatibility antigens in juvenile-onset diabetics, 26–29

**GLUCAGON**  
-binding mononuclear leukocytes in human blood, 127–131  
concentrations in diabetics with induced hypoglycemia  
autonomic neuropathy and, 628, 629, 631  
content of rat pancreas during postnatal development, 814–816  
deficiency  
and liver glucose production in dogs, 490–494  
and glycogenolysis and gluconeogenesis  
in conscious dog, 180–186  
immunoreactive effect of islet-activating protein on secretion of, in normal, alloxan-treated and depancreatized dogs, 430–434  
hepatic extraction of components of, 767–779  
immunoreactivity of ratfish islets, 192–195  
in totally duodeno-pancreatectomized and gastrectomized humans, 851–855  
-induced somatostatin release in perfused stomach of streptozotocin-diabetic rats  
pancreas transplantation and, 724–726  
and insulin levels in dogs  
exorphins and, 362–364  
oxytocin infusion and, 112–114  
and insulin requirements in postpancreatectomized patients, 641–642  
levels  
and exercise in diabetics and normals, 385

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1–88  
February, 89–174  
March, 175–270

April, 271–365  
May, 367–458  
June, 459–538

July, 539–620  
August, 621–704  
September, 705–796

October, 797–889  
November, 891–982  
Supplement 2, 1–110  
December, 983–1113

-like immunoreactivity, gut response to oral glucose  
in normal and gestational-diabetic pregnancy, 504-508  
-like immunoreactivity of pig gut transformation into pancreatic glucagon, 792-794  
in pancreatic specimens from infants of diabetic mothers, 271-273  
plasma glucose, insulin, and C-peptide response to injection of in normal and mildly and severely diabetic subjects, 685-692  
and recovery from hypoglycemia, 262-263  
responses to mixed meals in hypoglycemic patients and controls, 468, 469  
secretion from fetal mouse pancreas, effect of culture conditions on, 804-811  
in perfused rat pancreas, ethanol, acetaldehyde, and acetate and, 704-708  
veratridine and calcium and, 446-449  
and somatostatin suppression of insulin secretion in dogs portal and peripheral measurements and, 664-668  
-stimulated insulin release in triphenyltin fluoride-treated rabbits, 1016  
in stomach of human fetuses, 879-882

**GLUCOKINASE**

and adaptation of glycolytic enzymes in rat pancreas islets to starvation and refeeding, 924-928  
and regulation of glucose metabolism in rat pancreatic islets, 911-921

**GLUCONEOGENESIS**

and glycogenolysis in conscious dog differential time course of glucagon effect on, 180-186

**GLUCOSE**

and arachidonic acid- and epinephrine-induced platelet aggregation in insulin-dependent diabetics, \*45  
basal plasma brief, irregular oscillations of concentrations in diabetics, 435-439  
and calcium content of rat pancreatic islets, 52-54  
and calcium-dependent phosphatidylinositol breakdown and amylase secretion in rat pancreas, 396-401  
clearance and hyperglucagonemia in dogs, 185-186  
concentrations in isolated rat islets

and effects of prostacyclin and 6-keto-prostaglandin F<sub>1α</sub> on insulin secretion and cyclic AMP content, 824-827  
counterregulation in man, 261-263  
disposal measurement of, 847-850, 1000-1006  
and electrical activity in perfused, isolated mouse islets of Langerhans acetylcholine effects compared with, 558-561  
hepatic production in insulinoma patients insulin suppression of, 377-380  
high doses in neonatal rat model for non-insulin-dependent diabetes insulin, glucagon, and somatostatin responses to, 591-594  
homeostasis and idiopathic postabsorptive hypoglycemia, 465-469  
incorporation into cultured human fibroblasts, 403  
-induced hyperkalemia in diabetics and renin-angiotensin-aldosterone system, 335-339  
-induced insulin and glucagon secretion in perfused rat pancreas ethanol and acetaldehyde and acetate and, 705-708  
-induced insulin secretion in fetal and neonatal rat, 56-62  
and prostaglandin E synthesis in neonatal rat pancreas, 551-557  
and sites of action of trifluoperazine, 960-966  
in triphenyltin fluoride-treated rabbits, 1015-1016  
vincristine and, 539-544  
induced insulin release from rat pancreatic β-cells islet cell surface antibodies and complement and, 231-234  
zinc and, 341-344  
-induced insulin secretion in normal subjects correlation with urinary C-peptide excretion, 639-642  
infusions and evaluation of insulin action in diabetics, 650-655  
and insulin resistance and therapy in type II diabetics, 739-744  
and insulin infusions in normal man sympathetic nervous system activity and, 219-225  
and insulin and C-peptide response to glucagon injection in normals and mild and severe diabetics, 685-692  
insulin response to in familial obesity, 14-18  
intestinal uptake in diabetic rats, 247-255  
intolerance and atherosclerosis, \*50-52, \*58-59  
liver production and glucagon deficiency in dogs, 490-494  
loading test and effect of islet-activating protein in dogs, 432  
metabolic clearance rate and relationship of glucose utilization rate to glucose concentration, 847-850  
metabolism in rat pancreatic islets, and adaptation of glycolytic enzymes to starvation and refeeding, 923-928  
regulation in pancreatic islets, islet glucokinase, hexokinase, glyceraldehyde-P dehydrogenase, and P-fructokinase and, 911-922  
net disposal and insulin dose-response kinetics, in insulin-resistant non-insulin-dependent diabetics, 992  
and nonenzymatic glycosylation of rat glomerular basement membranes, 367-370  
oral gastrointestinal insulinotropic hormones response to in normal and gestational-diabetic pregnancy, 504-508  
insulin responses to, and atherosclerosis in diabetics and nondiabetics, \*54-57  
oxidation and iodination stimulated by polymorphonuclear leukocytes from insulin-treated diabetics, 256-259  
plasma insulin response to and atherosclerotic vascular disease risk, \*58-59  
production and uptake in normal dogs oxytocin infusions and, 112-114  
renal clearance of in diabetic ketoacidosis, 510-517  
and somatostatin, insulin and glucagon release compared to fructose, galactose, and ribose, 207-209  
and somatostatin and insulin secretion from isolated, perfused rat pancreas, 40-44  
and somatostatin release and D-cell recognition of D-glucose, 203-209  
and somatostatin suppression of insulin secretion in dogs portal and peripheral measurements and, 664-668  
-stimulated somatostatin and insulin release from isolated perfused rat pancreas

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

muscimol and, 168–170  
 tolerance  
 impaired, hypertriglyceridemia in diabetic humans and rats, and, 68–69  
 transfer from blood to bioartificial pancreas, 297, 298  
 transport  
 across ocular barriers in streptozotocin-diabetic rat, 903–905  
 by cultured human fibroblasts, effects of insulin and insulin-like agents on, 523–528  
 uptake  
 in different mouse skeletal muscles, 702–704  
 uptake by erythrocytes  
 in insulin receptor study in sheep, 412–414  
 utilization  
 and exercise in normal and diabetic subjects, insulin and, 983–988  
 during prolonged glucose clamp studies, 829–834  
 utilization and clearance in normal man  
 effects of plasma glucose concentration on, 535–537

**GLUCOSE CLAMP TECHNIQUE.** See  
*Euglycemic glucose clamp technique*

**<sup>14</sup>C-GLUCOSE**  
 and nonenzymatic glycosylation of rat glomerular basement membranes, 367–370

**GLUCOSE METABOLISM**  
 in fibroblasts from diabetics and nondiabetics  
 insulin and, 562–567  
 in genetically obese-diabetic mice, 211–217

**GLUCOSE OXIDASE METHOD, 115**  
 and plasma glucose levels in mice, 90

**GLUCOSE TOLERANCE**  
 in insulin-resistant non-insulin-dependent diabetics, 990, 992  
 in pregnancy, 504  
 and skeletal muscle morphology and enzyme activities, 19–25  
 and vincristine effects on glucose- and arginine-induced insulin release in rat pancreas, 539–544

**GLUCOSE TOLERANCE TESTS**  
 and diagnosis of postprandial hypoglycemia, 996–999  
 oral  
 chemical hypoglycemia after, and absence of hypoglycemia after mixed meals, 465–469  
 in hyperkalemic diabetics, 336, 337

in obese children of obese parents, 15–18  
 in streptozotocin diabetic rats with fetal pancreatic grafts, 10, 11–12

**<sup>13</sup>C-GLUCOSE**  
 and exercise and insulin, 983–988

**<sup>14</sup>C-L-GLUCOSE**  
 transport across ocular barriers in streptozotocin-diabetic rats, 903–905

**D-GLUCOSE**  
 pancreatic D-cell recognition of, 203–209

**$\beta$ -GLUCURONIDASE**  
 in diabetic and normal serum, 115–117

**$\alpha$ -GLUCOSIDE HYDROLASE INHIBITORS**  
 and carbohydrate absorption, 951–954

**GLUTAMIC ACID**  
 and insulin aggregation, 83–85

**GLUTEN**  
 digested and undigested  
 and postprandial insulin and glucagon levels in dogs, 362–364

**GLYCERALDEHYDE**  
 and somatostatin release from pancreatic D-cells, 205–207

**GLYCERALDEHYDE-P-DEHYDROGENASE**  
 and regulation of glucose metabolism in rat pancreatic islets, 915, 916

**GLYCOGEN SYNTHASE**  
 and effect of pH and 3-hydroxybutyrate on insulin binding and action in cultured human fibroblasts, 402–405  
 in fibroblasts of diabetics and nondiabetics, 564, 566  
 in skeletal muscle of genetically obese-diabetic mice  
 insulin and, 216

**GLYCOGENOLYSIS**  
 and gluconeogenesis in conscious dog differential time course of glucagon effect on, 180–186

**GLYCOHEMOGLOBIN**  
 labile  
 chemical means for removing in hemoglobin A, assay, 700–701

**GLYCOLYTIC INTERMEDIATES**  
 in erythrocytes from diabetics with ketoacidosis  
 insulin therapy and, 346–352

**GLYCOPROTEINS**

retrograde axonal transport in diabetic rats, 797–802  
 and serum glycosidase activity in diabetics and normals, 115

**GLYCOSAMINOLGLYCAN**

from kidneys of diabetic and normal Chinese hamsters, 393–395

**GLYCOSIDIC ENZYMES**

in serum of diabetics and normals, 115–117

**GLYCOSYLATION**

nonenzymatic  
 of low-density lipoproteins, 875–877  
 of rat glomerular basement membranes nonenzymatic, 367–370

**GONADECTOMY**

and expression of mutations at diabetes locus in male mice, 1036–1037, 1038

**GROWTH**

in diabetic and normal mice, 107  
 of fetal rat pancreas transplanted into streptozotocin-diabetic rats, 11–12  
 of RIN-r rat islet tumor cells in serum free medium  
 hormones and factors stimulating, 1022–1027

**GROWTH HORMONE**

and diabetic macroangiopathy, \*14–15, 16  
 and rabbit arterial myomedial cell growth, \*14–16  
 and rat islet tumor growth in serum-free medium, 1022–1027  
 responses  
 in hypoglycemic diabetics with and without autonomic neuropathy, 628, 631  
 and somatostatin action, 851–855

**H**

**HAMSTERS.** See Golden hamsters; Syrian hamsters

**H-2 HAPLOTYPE**

and expression of mutations at diabetes locus in mice, 1029–1034

**HASHIMOTO'S THYROIDITIS**

and diabetes in man, 1059–1060

DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1–88  
 February, 89–174  
 March, 175–270

April, 271–365  
 May, 367–458  
 June, 459–538

July, 539–620  
 August, 621–704  
 September, 705–796

October, 797–889  
 November, 891–982  
 Supplement 2, 1–110  
 December, 983–1113

**HEART**

cardiac arrhythmias during epinephrine-propranolol infusions for measurement of insulin resistance, 618-620  
 rat aorta  
 6-oxo-prostaglandin F<sub>1α</sub> production, diabetes, insulin, and caloric deprivation and, 935-938  
 rate  
 and insulin-induced hypoglycemia in diabetics with and without autonomic neuropathy, 630, 631, 632

**HEART DISEASE**

coronary  
 hypertension as risk factor in insulin-dependent juvenile onset diabetics for, \*90-96  
 in diabetes  
 and diabetic macroangiopathy and growth hormone, \*14-16  
 and diabetic microangiopathy and macroangiopathy, \*14  
 ischemic  
 and abnormal insulin response to glucose, \*54, \*55  
 in diabetics, \*49-50  
 and lipoproteins, \*4-5

**HEMOGLOBIN**

glycosylated  
 in clinical trial of aldose reductase inhibitor in diabetic neuropathy, 460, 461-462, 463  
 in diabetics and normals, 115  
 and insulin infusion pump in pregnant diabetics, 892-893  
 structure and synthesis in diabetics, 613-616  
 methods of measurement of, 614-615  
 irreversibly glycosylated  
 importance of estimation in diabetics, 607-612

**HEMOGLOBIN A<sub>1</sub>**

assays  
 and removal of labile glycohemoglobin, 700-701

**HEMOGLOBIN A<sub>1c</sub>**

and hypoxic arterial damage, \*2

**HEPARIN**

and fibrinogen survival in hyperglycemic diabetics, \*37

**HEREDITY**

acetylator phenotypes  
 in insulin-dependent diabetics with microvascular disease, 907-909  
 and expression of mutations at diabetes locus in mice

H-2 haplotype and sex and, 1029-1034, 1035-1043  
 nucleic acid antibodies in insulin-dependent diabetics and unaffected relatives, 873-874

**HEXOKINASE**

in gastrocnemius muscle tissue  
 fasting serum insulin and glucose tolerance and, 21-22, 24

**HEXOSE**

phosphorylation  
 and regulation of glucose metabolism in rat islets, 913-915  
 transport by fibroblasts  
 from diabetics and nondiabetics, 564, 566

**HEXOSE D-ALLOSE**

transport in perfused skeletal muscle of genetically obese-diabetic mice and glucose metabolism studies, 215-216

**HISTAMINE**

and microvessels of streptozotocin-diabetic Syrian hamsters, 97-98

**HISTOCOMPATIBILITY ANTIGENS**

and lymphocytotoxic antigens in juvenile-onset diabetics, 26-29

**HLA ANTIGENS**

and viral antibody titers  
 in insulin-dependent juvenile diabetics and controls, 584-589

**HLA-DR4 ANTIGENS**

and capillary basement membrane width in parents of children with type I diabetes, 475-479

**HOMOCYSTINURIA**

and endothelial injury  
 and platelet response, \*40

**HORMONES**

counterregulatory  
 in insulin-induced hypoglycemia in diabetics with and without autonomic neuropathy, 628-629, 630-632  
 and growth of cultured rat islet tumor cells, 1022-1027  
 insulinotropic  
 response to glucose in normal and gestational diabetic pregnancy, 504-508  
 sex steroids  
 and expression of mutations at diabetic locus in male mice, 1036-1039

and skeletal muscle metabolism in rats, 545-500

**HYALURONIC ACID**

in glycosaminoglycans from diabetic and normal Chinese hamster kidney cells, 393-395

**HYDROGEN**

production  
 and carbohydrate absorption study, 952, 953-954

**HYDROGEN CHLORIDE**

intragastric, and splanchnic somatostatin release in dogs  
 insulin and, 735-738

**HYDROGEN IONS**

in blood  
 in metabolic acidosis, 781-782

**β-HYDROXY-β-METHYLGLUTARYL-CoA REDUCTASE**

and cholesterol metabolism studies in diabetic rats, \*79-81

**3-HYDROXYBUTYRATE**

effects on insulin binding and action in cultured human fibroblasts, 402-405

and exercise in diabetics and normals, 985-986

renal clearance of  
 in diabetic ketoacidosis, 510-517

**P-HYDROXYPHENETHYLBIGUANIDE**

toxicity and hydroxylation study, 644-649

**HYPERCHLOREMIC ACIDOSIS**

mechanism of  
 during recovery phases of diabetic ketoacidosis, 310-313

**HYPERCHOLESTEROLEMIA**

arterial injury and  
 atherosclerosis and, \*9  
 and coronary artery disease, \*4  
 in endothelial cell injury studies, \*40-41  
 and impaired endothelial cell migration, \*41

**HYPERGLUCAGONEMIA**

and glycogenolysis and gluconeogenesis in dogs, 180-186

**HYPERGLYCEMIA**

atherosclerosis and, \*2, \*49-53  
 and hyperinsulinemia, \*5  
 and blood clotting assays in diabetics, \*35

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
 February, 89-174  
 March, 175-270

April, 271-365  
 May, 367-458  
 June, 459-538

July, 539-620  
 August, 621-704  
 September, 705-796

October, 797-889  
 November, 891-982  
 Supplement 2, 1-110  
 December, 983-1113

and blood glucose levels in genetically diabetic mice, 91  
and blood platelet survival in diabetics, 486-489

control  
and measurement of glycosylated hemoglobins, 616  
2-deoxyglucose-induced  
and wound healing in mice, 407-410  
and increased dopamine- $\beta$ -hydroxylase activity in streptozotocin-diabetic rats, 418-419  
and insulin withdrawal in totally duodenal-pancreatectomized humans  
and somatostatin, 851-855  
and intestinal sugar flux in rats, 570  
islet mass and B-cell function loss preceding  
in mice given multiple low doses of streptozotocin, 424-429

maternal  
and infant hyperglycemia, 271, 273  
and microangiopathy in cold-adapted eel, 317-325  
onset in mice after streptozotocin doses age and, 718-722  
in pregnant diabetics with insulin infusion pumps, 894  
streptozotocin-induced in neonatal rat islets, 64-69  
and sympathetic nervous system activity in normal man, 219-225  
and vascular volume, \*34

#### **HYPERINSULINEMIA**

and atherosclerosis, \*5  
and dietary control in diabetic mice, 109, 110  
and hypoglycemia in insulinemia patients, 377-380  
in non-insulin-dependent diabetics, \*2  
in obese offspring of obese parents, 14-18  
in prolonged glucose clamp studies and glucose utilization, 829-834  
and sympathetic nervous system activity in normal man, 219-225

#### **HYPERKALEMIA**

and diabetes  
and renin-angiotensin-aldosterone system, 335-339

#### **HYPERLIPIDEMIA**

and endothelial cell injury studies, \*40-41  
and hemostasis in diabetes, \*33-34

#### **HYPERTHROPHIA**

and hypercholesterolemia in diabetic rats, \*80-81

#### **HYPERSOMATOSTATINEMIA**

of insulin deficiency  
and high plasma free fatty acid levels, 358-360

#### **HYPERTENSION**

and arterial stiffening, \*101  
and endothelial injury, \*2  
insulin and, 224-225  
in juvenile-onset insulin-dependent diabetics, 178  
as risk factor for renal and coronary heart disease  
in juvenile-onset diabetics, \*90-96, \*105

#### **HYPERTRIGLYCERIDEMIA**

and coronary artery disease, \*4-5  
diabetic  
in insulin-dependent and non-insulin-dependent diabetics and streptozotocin-diabetic and nondiabetic rats, \*66-74  
in rabbits  
triphenyltin fluoride-induced, 1013-1020

#### **HYPOALANINEMIA**

in pregnancy  
and skeletal muscle metabolism, 545-550

#### **HYPOGLUCAGONEMIA**

and liver glucose production in dogs, 490-494

#### **HYPOLYCEMIA**

and diabetic pregnancy  
and insulin infusion pump, 893, 894, 895  
glucose recovery from adrenergic blockade and, 261-263  
hyperinsulinemia, and nesidioblastosis in neonates  
pancreatic somatostatin decrease and, 122-125  
idiopathic postabsorptive, 465-469  
insulin-induced in diabetics with and without autonomic neuropathy  
hormonal, metabolic, and cardiovascular responses to, 626-632  
in insulinoma patients:  
insulin suppression of hepatic glucose production and, 377-380  
postprandial  
diagnosis of, 996-999  
in pregnancy  
and skeletal muscle metabolism, 545-550

#### **HYPOPHOSPHATEMIA**

and insulin responses in dogs, 384

#### **HYPOTENSION**

postural  
in aldose reductase inhibition trial in diabetic neuropathy, 461

#### **HYPOXIA**

and endothelial cells and smooth muscle cells in low oxygen environment  
atherosclerosis and, \*41

#### **IBUPROFEN**

and inhibition of prostaglandin E synthesis in neonatal rat pancreatic cells  
insulin secretion and, 551-556

#### **IMMUNE COMPLEXES**

soluble, from diabetic serum  
platelet aggregation and ATP release after incubation with, 575-578

#### **IMMUNIZATION**

pneumococcal  
in adult diabetics, 119-121

#### **IMMUNOCYTOCHEMICAL STAINING STUDIES**

and pancreas islet A-, B-, and D-cell populations  
in postnatal rats, 813-817  
of pancreatic tissue from neonates with nesidioblastosis, 122-125

#### **IMMUNOFLUORESCENCE STUDIES**

of diabetogenic drug inhibition of superoxide dismutase, 236-237, 239-240  
and effects of streptozotocin on mouse pancreas  
age and, 719-720, 722  
of isolated mouse islets after incubation with serum from diabetic patients with complement-fixing islet cell antibodies, 1051-1056  
of kidney basement membrane albumin concentrations in diabetics and nondiabetics, 844-845  
of lymphocyte hybrid cells, 227  
of ratfish islet cells  
and glucagon immunoreactivity study, 192-195  
of renal cortex from diabetic mice  
dietary control and, 107, 108-111

#### **IMMUNOGLOBULIN**

and autoantibodies against insulin receptor study, 354-357

#### **DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

**IMMUNOGLOBULIN G**

and affinity chromatography, 471-472, 473-474  
extravasation into cerebral cortex of diabetic rats, 500-503  
stimulatory effect on adipocyte lipogenesis, 1068-1071  
transferrin clearance ratios as index for protein excretion, 658, 659, 661, 662

**IMMUNOHISTOCHEMICAL STUDIES**

of plasma protein extravasation into cerebral cortex of diabetic rats, 500-503  
of rat islet tissues and adenomas from nicotinamide and streptozotocin-treated rats, 305-307

**IMMUNOLOGY**

and arterial injury, \*9, \*31  
and induction of complement-dependent antibody cytotoxic to cultured beta cells in mice, 30-38  
and pneumococcal immunization in adult diabetics, 119-121

**IMPOTENCE**

and aldose reductase inhibition in diabetic neuropathy, 461

**INDOMETHACIN**

and prostaglandin E synthesis by rat pancreas, 553

**INFANTS**

of diabetic mothers immunocytochemical study of pancreatic specimens from, 271-273 and insulin infusion pump during pregnancy, 894-895 with hypoglycemia, hyperinsulinemia and nesidioblastosis and pancreatic somatostatin decrease, 122-125

**INFECTION, See also Wound healing and diabetes**

and pneumococcal immunization in adult diabetics, 119-121

**INSECTS**

*Drosophila melanogaster* insulin content, 70-75

**INSULIN**

action and insulin receptor defects, 149 and postreceptor defects, 149-150 action and response in diabetic hypertriglyceridemia studies, \*67

**aggregation**

dicarboxylic amino acids and prevention of, 83-85

**antisera to**

and wound healing in mice, 407-410 and arterial wall lipid metabolism in streptozotocin-diabetic rats, \*55

**assays**

of fetal pancreatic grafts in adult streptozotocin-diabetic rats, 10

**basal plasma**

brief, irregular oscillations of concentrations in diabetics, 435-439

**binding**

in different mouse skeletal muscles, 702-704

by erythrocytes and monocytes in normal and disease states, 896-901

wheat germ agglutinin-induced tissue differences in, 196-201

binding, internalization, and insulin receptor regulation in fibroblasts from non-insulin-dependent diabetics, 596-600

binding and action in cultured human fibroblasts effect of pH and 3-hydroxybutyrate on, 402-405 from maturity-onset of the young diabetics, 940-945

binding to isolated bovine brain microvessels, 757-761

**binding to lymphocytes**

inhibition by naturally occurring anti-receptor antibodies, 979-981

**cardiotonic effects of**

224-225

circulating hormonal and nonhormonal antagonists, 149

content, synthesis, and glucose-induced secretion in cultured rat pancreatic islets myo-inositol concentrations and, 621-625

**content of rat pancreas**

during postnatal development, 814-816

**continuous subcutaneous infusion**

and exercise-induced microalbuminuria in insulin-dependent diabetic men, 818-822

**deficiency**

hypersomatostatinemia of, high plasma free fatty acid levels and, 358-360

and increased sugar transport in streptozotocin-diabetic rats, 570-571

**delivery by artificial pancreas**

correlation between carbohydrate and, 101-105

**-dependent diabetics**

and albumin deposition in dermal capillary basement membrane, 275-278

antibodies to nucleic acids in, 873-874

continuous subcutaneous insulin infusion and correction of exercise-induced microalbuminuria in, 818-822

dietary carbohydrate and insulin delivery by artificial pancreas in, 101-105

high density lipoprotein composition in, 132-137

and lipoprotein metabolism, \*88-89 platelet arachidonic acid metabolism in, \*44-47

prospective study of viral titers and HLA antigens in, 584-589

in rats, and lymphocytic thyroiditis, 1058-1060

Registry in Allegheny County, Pennsylvania, 279-283

**-dependent juvenile diabetes**

effect of pubertal stage and recent blood glucose control on somatomedin C in, 868-871

hypertension as risk factor for renal and coronary heart disease in, \*90-96

long-term study of mortality and vascular complications, 175-178

lymphocytotoxic antibodies and histocompatibility antigens in, 26-29

dependent and nondependent diabetes and high density lipoprotein metabolism, \*84-86

**dosage**

and insulin infusion pump in pregnant diabetics, 892, 893-894

and plasma somatomedin C in juvenile diabetics, pubertal stage and, 868-871

dose-response kinetics for glucose disposal

in insulin resistance studies in non-insulin-dependent diabetics, 990-992

effect on arterial lesions, \*55

effect on cultured monkey arterial cells, \*55-56

**fasting serum levels**

and body weight and skeletal muscle morphology and enzyme activity, 19-25

gastrointestinal absorption in rats and sodium 5-methoxysalicylate, 1065-1066

**gene**

location of, 267-270

and glomerular lesions in streptozotocin-diabetic rats, 111

and glucagon levels in dogs

exorphins and, 362-364

oxytocin infusion and, 112-114

and glucose infusions in normal man sympathetic nervous system activity and, 219-225

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

- and glucose and C-peptide response to glucagon injection  
in mild and severe diabetics and normal subjects, 685-692
- glucose-stimulated release from isolated perfused rat pancreas  
muscimol and, 168-170
- and glucose transport by cultured human fibroblasts, 523-528
- and glucose uptake and metabolism by skeletal muscle from genetically obese-diabetic mice, 214
- and glucose utilization during exercise in normal and diabetic subjects, 983-988
- and glycogen synthase and pyruvate dehydrogenase activities in skeletal muscle of genetically obese-diabetic mice, 216
- and glycolytic intermediary metabolism in erythrocytes during diabetic ketoacidosis, 346-352
- and hepatic fructose 2,6-bisphosphate levels in alloxan-diabetic starved rats, 1062-1064
- and hepatic glucose production and suppression of hypoglycemia in insulinoma patients, 377-380
- and high-density lipoprotein metabolism, \*83-84
- highly purified porcine compared with highly purified bovine and conventional insulins  
tissue sensitivity studies in diabetics, 650-655
- and hyperphagia and hypercholesterolemia, \*80-81
- immunoreactive  
in diabetic and normal mice, 108, 110  
effect of islet-activating protein on secretion of, 430-434
- incomplete conversion of proinsulin to, 148
- induced hypoglycemia in diabetics with and without autonomic neuropathy  
hormonal, metabolic, and cardiovascular responses to, 626-632
- induced insulin resistance in vitro, 155-157
- induced receptor loss and insulin internalization  
in isolated rat adipocytes, 746-752
- infusion  
with long-term continuous intraperitoneal insulin infusion device, 1073-1074
- in insects and annelids, 70-75
- and insulin secretagogues effects on calcium-dependent phosphatidyl-inositol breakdown and amylase secretion in rat pancreas, 396-401
- and intravenous glucose disposal  
indirect calorimetry and hepatic and femoral venous catheterization in study of, 1000-1006
- and iodotyrosine metabolism  
in streptozotocin-diabetic rats, 697-698
- levels in hypoglycagemonic dogs  
liver glucose production and, 491-492
- like growth factor  
and glucose transport by cultured human fibroblasts, 523-528
- liver and pancreas content  
in pancreatic islet allograft survival study, 947-948
- open-loop administration in severely insulin-deficient patients  
waveform requirements study, 710-716
- and ornithine decarboxylase regulation in rat skeletal muscle, 682-683
- pancreatic content  
in infants of diabetic mothers, 271-273
- and protein- and acid-induced splanchnic somatostatin release in dogs, 735-738
- and rat aorta 6-oxo-prostaglandin F<sub>1α</sub> production, 935-938
- and rat islet tumor growth in serum-free medium, 1022-1027
- recombined A and B-chains of synthetic human and pancreatic pork immunologic potency of, 265-266
- release  
glucose, glucagon, and arginine-stimulated, in triphenyltin fluoride-treated rabbits, 1016-1017
- and glucose and acetylcholine effects on electrical activity in pancreatic islet cell membrane, 558-561
- glucose- and arginine-induced, vincristine and, 539-544
- glucose-stimulated, trifluoperazine sites of action in inhibition of, 960-966
- and glucose stimulation of calcium in rat pancreatic islets, 52-54
- from islet tissues and adenomas of rats treated with nicotinamide and streptozotocin, 302-308
- 3-isobutyl-1-methyl-xanthine priming effect in isolated rat islets of Langerhans, 754-756
- from isolated mouse islets, and incubation with complement-fixing islet cell antibodies from diabetics, 1051-1056
- in rat pancreatic islets during fasting and refeeding, 923-928
- in study of regulation of glucose metabolism in rat pancreatic islets, 917-918
- release from column-perfused rat pancreatic B-cells
- islet cell surface antibodies and complement and, 231-234  
and renal hypertrophy in diabetic animals, 485
- requirements  
in postpancreatectomy patients, 641-642
- resistance  
assessment with insulin suppression test and euglycemic clamp, 387-392
- causes of, 148-151
- and circulating insulin antagonists, 149
- epinephrine-propranolol infusions for measurement of, cardiac arrhythmias during, 618-620
- and hyperinsulinemia in non-insulin-dependent diabetics, \*2
- insulin antibody-mediated, and semisynthetic insulin analogues, 519-522
- and insulin binding to erythrocytes and monocytes, 900
- insulin-induced in vitro, 155-157  
in non-insulin-dependent diabetics, 157-160, 990-995
- in non-insulin-dependent diabetics, fibroblast studies and, 562-566  
in obesity, 151-155
- and post-receptor defects, 149-151
- in pregnancy, skeletal muscle metabolism and, 545-550
- resistance and action in vitro and in vivo, 148-161
- response to glucose  
and colchicine, 1008-1012  
in normal and gestational-diabetic pregnancy, 504-508
- response to high glucose and arginine in neonatal rat model for non-insulin-dependent diabetes, 591, 594
- responses  
and subcutaneous, isogenic transplantation of duct-ligated pancreas in diabetic mice, 857-863
- role in atherosclerosis  
in diabetics and nondiabetics, \*54-57
- secretion  
colchicine and, 1008-1012  
and 1,25 dihydroxyvitamin D<sub>3</sub> in Vitamin D-deficient rats, 382-385  
from fetal mouse pancreas, effect of culture conditions on, 804-811  
glucose-induced, in fetal and neonatal rat, 56-62  
by islets from new animal model for non-insulin-dependent diabetes, 590-594
- from isolated, perfused rat pancreas, glucose and cyclic AMP and, 40-44
- in perfused rat pancreas, ethanol, acetaldehyde, and acetate

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88	April, 271-365	July, 539-620	October, 797-889
February, 89-174	May, 367-458	August, 621-704	November, 891-982
March, 175-270	June, 459-538	September, 705-796	Supplement 2, 1-110
			December, 983-1113

and, 704–708  
and prostaglandin E synthesis in neonatal rat pancreas, 551–556  
somatostatin suppression of, portal vein hormone measurements and, 664–668  
veratridine and calcium and, 446–449  
secretion from isolated rat islets  
age and, 77–82  
prostacyclin and 6-keto-prostaglandin F<sub>1α</sub> and, 824–827  
zinc-induced inhibition of, 341–344  
secretion rates in normal subjects  
correlation with urinary C-peptide excretion, 639–642  
semisynthetic analogues with different amino acids  
immunoreactivity and biological activity of, 519–522  
sensitivity  
in skeletal muscle of genetically obese mice, 211–217  
and streptozotocin diabetes in rats  
adipose tissue cyclic AMP phosphodiesterase and protein activator and, 372–375  
synthesis by recombinant DNA methodology, 265–266  
therapy  
and insulin resistance in type II diabetics, diabetes classifications and, 739–744  
and pancreatic somatostatin secretion abnormalities in streptozotocin-diabetic rats, 865–867  
in streptozotocin-diabetic rats, regional localization of cerebral edema following, 762–766  
-treated diabetics  
and polymorphonuclear leukocytes-stimulated glucose oxidation and iodination in, 256–259  
treatment of streptozotocin-diabetic Syrian hamsters  
and microvascular studies, 95, 98, 100  
uptake of kidney, 929–933

#### **INSULIN-DEPENDENT DIABETES MELLITUS REGISTRY, 279–283**

**INSULIN INFUSION SYSTEMS**  
in diabetic pregnancy, 891–895  
long-term continuous intraperitoneal, 1073–1074

**INSULIN RECEPTORS**  
absence on resting lymphocytes, 314–316  
antibodies against, 149  
autoantibodies against mechanism of, 354–357  
and simultaneously occurring autoan-

tibodies against somatomedin-C receptors, 979–981  
and binding potency of recombined synthetic human and pancreatic port insulins, 265–266  
on bovine brain microvessels, 757–761  
cryptic  
and hypertonic salt solutions or enzymatic digestion of lymphocytes, 314–416  
defects, 149  
erythrocyte  
disappearance during maturation in sheep, 411–414  
of erythrocytes and monocytes in normal and disease states in man, 896–901  
in fibroblasts from non-insulin-dependent diabetics  
insulin regulation and, 596–600  
insulin-induced loss in isolated rat adipocytes  
and internalization of insulin receptors, 746–752  
and insulin resistance in non-insulin-dependent diabetics, 990–995  
membrane lipid environment effects on, 773–779  
in rat adipocytes and hepatocytes and human lymphocytes  
<sup>125</sup>I-insulin binding in, 4–5  
tissue differences in, 196–201

#### **INSULIN SUPPRESSION TEST**

assessment of insulin resistance with, 387–392

#### **INSULIN TOLERANCE TESTS**

and triphenyltin fluoride in rabbits, 1017

#### **<sup>125</sup>I-INSULIN**

and autoantibodies against insulin receptor study, 354–357  
binding to capillaries from bovine cerebral cortex, 757–761  
in insulin binding studies in fibroblasts from non-insulin-dependent diabetics, 596–600  
preparation, biologic properties and long-term stability, 1–8  
tyrosine A14 [<sup>125</sup>I]monoiodoinsulin, 1–8

#### **INSULINOMA**

and hypoglycemia  
and insulin suppression of hepatic glucose production, 377–380  
and insulin binding by erythrocytes and monocytes, 896–901

#### **INTERMITTENT CLAUDICATION SYNDROME**

in diabetics, \*49–50

**ODOACETATE**  
and renal insulin uptake, 930–933

**ODOTYRONINE**  
metabolism  
in diabetic rats, 694–698

**ISLET-ACTIVATING PROTEIN**  
and immunoreactive insulin and glucagon secretion  
in normal, alloxan-treated, and depancreatized dogs, 430–434

**ISLETS OF LANGERHANS.** See also Pancreas islets  
D-cells somatostatin production  
diabetes and, 188  
inhibition of superoxide dismutase by diabetogenic drugs, 236–240  
isolated perfused mouse  
and glucose and acetylcholine effects on electrical activity in, 558–561  
isolated rat  
3-isobutyl-1-methyl-xanthine priming effect on insulin release in, 754–756  
zinc-induced inhibition of insulin secretion from, 341–344

**3-ISOBUTYL-1-METHYL-XANTHINE**  
and insulin release in isolated rat islets of Langerhans, 754–756  
and prostaglandin inhibition of insulin secretion in isolated rat islets, 826–827

**ISONIAZID**  
acetylation  
and slow and fast acetylators, peripheral neuropathy and, 907

**ISOPROTERENOL**  
and insulin secretion by islets from new animal model for non-insulin-dependent diabetes, 591–592, 594

#### **J**

**JAPANESE**  
diabetics  
atherosclerosis incidence in, \*1

**JUVENILE DIABETES**  
and capillary basement membrane width and HLA antigens in parents of type 1, 475–479  
and continuous central venous insulin infusion  
waveform requirements for metabolic normalization, 710–716

#### **DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1–88  
February, 89–174  
March, 175–270

April, 271–365  
May, 367–458  
June, 459–538

July, 539–620  
August, 621–704  
September, 705–796

October, 797–889  
November, 891–982  
Supplement 2, 1–110  
December, 983–1113

insulin-dependent  
  effects of pubertal stage and recent blood glucose control on plasma somatomedin C in, 868-871  
hypertension as risk factor for renal and coronary heart disease in, \*90-96  
prospective study of viral titers and HLA antigens in, 584-589  
insulin requirements, 642  
mortality and vascular complications long-term study, 175-178

**K**

**KETOACIDOSIS, DIABETIC**  
and erythrocytes glycolytic intermediary metabolism, 346-352  
mechanism of hyperchloremic acidosis during recovery phase of, 310-313  
mortality and, 1  
pathophysiological aspects of, 781-786  
renal function and effects of partial rehydration during, 510-517

**KETOAMINE**

-linked glucose  
in collagen of glomerular basement membrane from diabetic rats, 616

**KETONE BODIES**

and acid-base balance, 517  
anion concentration in diabetic ketoacidosis, 782-783  
renal handling during diabetic ketoacidosis, 516-517  
urinary excretion in diabetic ketoacidosis, 510-511

**6-KETO-PROSTAGLANDIN F<sub>1α</sub>**

and insulin secretion and cyclic AMP content of rat isolated islets, 824-827

**KIDNEY**

basement membrane  
  albumin concentrations in diabetes, 843-845  
clearance of specific plasma proteins  
  diabetes duration and, 656-662  
of diabetic and normal Chinese hamsters  
analysis of glycosaminoglycan from, 393-395  
disease  
  hypertension as risk factor in insulin-dependent juvenile diabetes for, \*90-96

function  
  and partial rehydration during diabetic ketoacidosis, 510-517  
and subcutaneous insulin infusion in insulin-dependent diabetics, exercise-induced microalbuminuria and, 818-822  
glomerular basement membrane accumulation in streptozotocin-diabetic rats  
  islet cell transplantation and, 481-485  
glomerular lesions in streptozotocin-diabetic rats  
  insulin or pancreatic transplantation and, 111  
growth  
  and streptozotocin-induced diabetes, 484  
insulin uptake, 929-933  
nephropathy  
  dietary control and prevention in diabetic mice of, 106-111  
rat glomerular basement membrane  
  nonenzymatic glycosylation of, 367-370  
reabsorption and excretion rates of ketone bodies  
  in diabetic ketoacidosis, 516-517  
tubular basement membrane  
  albumin content in diabetes, 843-845

**L**

**LACTATE DEHYDROGENASE**  
in gastrocnemius muscle tissue  
  fasting serum insulin and glucose tolerance and, 21-22, 24

**LECTIN.** See Wheat germ agglutinin

**"LEPRECHAUNISM"**  
and beta-cell hyperplasia, 150

**LESIONS**

arterial  
  insulin effect on, \*55  
atherosclerotic  
  and injury to arterial wall, \*8-12  
encephalomyocarditis-induced in mouse pancreas islets  
  genetic obesity and, 451-454  
glomerular  
  in streptozotocin-diabetic rats, insulin or pancreatic transplantation and, 111

**LEUKOCYTES.** See also Mononuclear leukocytes  
and contamination of islet allograft preparations, 242-246  
and immune rejection in transplants, 285-290

**polymorphonuclear**  
from insulin-treated diabetics, decreased stimulated glucose oxidation and iodination by, 256-259

**LINOLEATE**

-enrichment of Friend erythroleukemia cells media  
effects on insulin receptors, 773-779

**LIPIDS**

accumulation in atherosclerotic lesions induced in rabbit aorta, \*12  
metabolism  
  in cultured rat arterial smooth muscle cells, insulin and, \*56-57  
and endothelial cell biology, \*19-22  
in streptozotocin-diabetic rat arteries, \*55

**LIPOGENESIS**

adipocyte  
  immunoglobulin G stimulatory effect on, 1068-1071  
and insulin-induced hypoglycemia in diabetics with and without autonomic neuropathy, 628, 630-631  
norepinephrine-induced in isolated rat adipocytes  
  prostaglandin production and, 163-166

**LIPOPROTEIN LIPASE**

of adipose tissue  
  in obese diabetics and nondiabetics, \*86  
in gastrocnemius muscle tissue  
  fasting serum insulin and glucose intolerance and, 21-22, 24  
and triphenyltin fluoride treatment in rabbits, 1016, 1017-1018

**LIPOPROTEINS**

and atherogenesis in diabetics, \*4-5  
endothelial cell biology, \*19-22  
epithelial cell block to interiorization of, \*20-21  
high-density  
  alterations by cholesterol feeding, \*62-63  
composition in insulin-dependent diabetics, 132-137  
and diabetes, \*5, \*82-86  
and diabetic atherosclerosis, \*86  
metabolism of, \*82-86  
low-density  
  atherosclerosis incidence and, \*19, \*88  
and endothelial damage, \*2  
and high fat-high cholesterol diets, \*64  
nonenzymatic glycosylation studies, 875-877

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

- metabolism**  
 in atherosclerosis, \*60-65  
 in diabetes, \*88-89  
 and dietary alteration of degree of sialylation of ApoC-III, 530-533  
 and hyperinsulinemia, \*5  
**patterns**  
 in obese children of obese parents, 15-17  
**triglyceride-rich**  
 endothelial cell uptake of, \*21-22  
 uptake into arterial smooth muscle cells, \*5  
**very-low-density**  
 plasma removal of, 496-499  
**very-low-density remnant**  
 atherogenesis in diabetes and, \*4-5  
**very-low-density-triglyceride secretion rate**  
 in diabetic hypertriglyceridemia, \*67  
**B-very-low-density**  
 and origins of cholesterol-accumulating foam cells in arterial walls, \*63-64
- LIVER**  
 extraction of plasma immunoreactive glucagon components in dogs, 767-779  
 glucose production  
   and glucagon deficiency in dogs, 490-494  
 glucose production in insulinoma patients  
   insulin therapy and, 377-380  
 glycogenolysis and gluconeogenesis in conscious dog  
   glucagon and, 180-186  
 and iodotyrosine metabolism  
   in diabetic rats, 694-698  
 mean fractional insulin extraction  
   and calculation of insulin secretion rates in normal subjects, 639-642  
 mitochondria  
   inhibition of superoxide dismutase by diabetogenic drugs, 236-240  
 rat  
   fructose 2,6-bisphosphate levels, effects of diabetes, insulin, starvation and refeeding on, 1062-1064  
   insulin binding studies, 196-201  
 and secretion of  $\beta$ -very-low-density lipoproteins, \*63-64  
 and transplantation of islet xenografts into diabetic mice via portal vein, 285-290  
 triglyceride secretion  
   in streptozotocin-diabetic rats, \*68  
 venous catheter technique  
   and effect of insulin on intravenous glucose disposal, 1000-1006
- and intravenous glucose disposal and insulin study, 1000-1006
- LYMPH**  
 flow rate and triglyceride levels in thoracic duct of normal and vagotomized dogs  
 somatostatin and, 440-444
- LYMPHOCYTES**  
 B- and T-cell  
   in spontaneously diabetic rats, 887-889  
 cultured human  
   and autoantibodies against insulin receptor studies, 354-357  
    $^{125}\text{I}$ -insulin binding in, 4-5  
 cultured human IM-9  
   simultaneous inhibition of insulin and somatomedin-C binding to, 979-981  
 infiltration of pancreatic islets  
   and multiple low doses of streptozotocin in mice, 424-429  
 mice  
   hybrid cell antibodies reacting with rat islet cell membrane antigens, 226-230  
 and rejection of islet xenografts in diabetic mice, 285-290  
 stimulated and resting  
   and insulin receptors, 314-316  
 T-cell  
   and rejection of established islet allografts, 242-246
- LYMPHOID CELLS**  
 and islet xenograft survival, 285-290
- LYSINE ACETYL SALICYLATE**  
 and colchicine inhibition of insulin secretion, 1010-1012
- M**
- MACROANGIOPATHY, DIABETIC**  
 and endothelial cells of large and small vessels, \*24-27  
 growth hormone and, \*14-16
- MACROPHAGES**  
 and atherosclerotic lesions, \*63, \*64
- MAGE VALUES**  
 and insulin infusion pump in pregnant diabetics, 894-895
- MANNOHEPTULOSE**  
 and glucose- and glyceraldehyde-induced somatostatin, insulin and glucagon release by pancreatic D-cells, 207
- MAREK'S DISEASE**  
 in chickens  
   and atherosclerosis, \*29-31
- MENSTRUAL CYCLE**  
 and erythrocyte and monocyte insulin binding, 901
- METABOLISM**  
 arterial wall  
   and atherogenesis, \*5  
 cartilage and bone proteoglycans biosynthesis  
   in streptozotocin-diabetic rats, 670-677  
 cholesterol  
   in diabetes, role of diet in, \*76-81  
   in endothelial cells, \*20  
 composite energy, in peripheral nerve axons and Schwann cells  
   in alloxan-diabetic rabbits, 967-974  
 exercise-induced microalbuminuria in insulin-dependent diabetics  
   continuous subcutaneous insulin infusion and, 818-822
- glucose  
   in genetically obese-diabetic mice, 211-217  
   and prolonged glucose clamp studies, 829-834  
   in rat pancreatic islets, and adaptation of glycolytic enzymes to starving and refeeding, 923-928  
 regulation in rat pancreas islets, 911-922  
 glucose counterregulation in man, 261-263  
 glucose metabolic clearance rate models, 847-850  
 glycolytic intermediary in erythrocytes and diabetic ketoacidosis, 346-352  
 of high density lipoproteins, \*82-83  
 insulin and, \*83-84  
   in insulin-dependent diabetes, \*84-85  
   in non-insulin-dependent diabetics, \*85-86  
 insulin, glucagon, and glucose and oxytocin infusions in normal dogs, 112-114  
 insulin uptake by kidney, 929-933  
 iodotyrosine  
   in streptozotocin-diabetic rats, 694-698  
 lipid  
   in cultured rat arterial smooth muscle cells, insulin and, \*56-57  
   and endothelial cell biology, \*19-22  
 lipoprotein  
   in atherosclerosis, \*60-65  
   in diabetes, \*88-89  
 plasma glucose utilization and glucose clearance in normal man  
   effects of plasma glucose concentration on, 535-537

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88	April, 271-365	July, 539-620	October, 797-889
February, 89-174	May, 367-458	August, 621-704	November, 891-982
March, 175-270	June, 459-538	September, 705-796	Supplement 2, 1-110
			December, 983-1113

- platelet arachidonic acid  
in diabetics, \*44-47
- rat skeletal muscle  
effects of pregnancy and sex steroids  
on, 545-550
- 3-O-METHYL-D-GLUCOSE**  
transport across ocular barriers in streptozotocin-diabetic rats, 903-905
- MICE**
- diabetic
    - prolongation of islet xenograft survival in, 285-290
    - expression of mutations at diabetic locus in
      - and male lethal syndrome, 1035-1043
    - genetically diabetic
      - diet control and prevention of diabetic nephropathy in, 106-111
      - and H-2 haplotype and sex, 1029-1034
    - platelet aggregation in cerebral and mesenteric microcirculation, 89-92
    - genetically obese
      - and encephalomyocarditis-virus-induced diabetes, 451-454
      - genetically obese-diabetic hormone regulation of glucose metabolism in, 211-217
      - injection of complement-dependent islet cell antibodies into, 30-38
      - islets
        - incubated with serum from diabetic patients with complement-fixing islet cell antibodies, 1051-1056
        - lymphocyte hybrid cell antibodies reaction with rat islet cell membrane antigens, 226-230
        - and multiple low doses of streptozotocin
        - islet mass and B-cell function loss preceding hyperglycemia in, 424-429
      - normal and genetically obese
        - effect of sucrose overfeeding on Na, K-ATPase-mediated potassium uptake in, 975-978
      - perfused, isolated islets of Langerhans effects of glucose and acetylcholine on electrical activity in, 558-561
      - skeletal muscles
        - insulin binding and glucose uptake differences in different types of, 702-704
      - streptozotocin damage and age study, 718-722
      - and streptozotocin-diabetes induced with multiple low doses of streptozotocin
        - and exogenous superoxide dismutase, 634-638
- streptozotocin-diabetic  
subcutaneous, isogenic transplants of duct-ligated pancreas, glucose tolerance studies in, 857-863
- wound healing in  
effect of antisera to insulin, 2-deoxyglucose-induced hyperglycemia, and starvation on, 407-410
- MICROANGIOPATHY, DIABETIC**
- and endothelial cells of large and small vessels, \*24-27
  - and enhanced platelet aggregation and soluble immune complexes from diabetic serum, 575-578
  - and hyperglycemia in cold-adapted eel, 317-325
  - and microvascular alterations in streptozotocin-diabetic Syrian hamsters, 93-100
- MICROSCOPY**
- of coronary arteries from cholesterol-fed miniature swine, \*60, \*61
  - electron and beta-cell necrosis in diabetic mice, 663
  - and capillary basement membrane width study in parents of children with type 1 diabetes, 475-479
  - and demonstration of glucagon in human fetal stomach, 879-882
  - of kidneys from islet cell transplanted streptozotocin-diabetic rats, 482-485
  - and microthrombus formation in retinal vessels in streptozotocin-diabetic rats, 601-606
  - of pancreas B-cell microtubular structures, vincristine effects on glucose-induced insulin release and, 539-544
  - of rabbit beta cells after triphenyltin fluoride treatment, 1017
  - electron and transmission
    - of blood capillaries of cold-adapted eels, 318, 319-322
  - immunofluorescence
    - of dermal capillary basement membrane of insulin-dependent diabetics, albumin deposition in, 275-278
    - in microvessel studies of streptozotocin-diabetic Syrian hamsters, 94-100
  - of injured rabbit aorta and atherosclerotic lesions, \*8
  - light
    - of fetal mouse pancreas in organ culture effects study, 807
    - in islet xenograft survival study in diabetic mice, 285, 286, 288-290
    - of kidneys from islet-cell transplanted streptozotocin-diabetic rats, 482
- of mouse pancreas after induction of complement-dependent antibody cytotoxicity to cultured beta cells, 33-38
- of pancreatic islet allografts after blood transfusion and ALS treatment in rats, 948, 949
- and renal histology in diabetic mice, 107, 108, 109-111
- of skeletal muscle capillaries of diabetics, 327, 330-331
- of streptozotocin-diabetic rat cartilage and bone, 672, 673
- light and electron
  - of neonatal pig pseudo-islets, 580-583
- light and immunocytochemical
  - and effects of streptozotocin on islet cells in rats, 426, 428-429
- mouse islets
  - and diabetes gene expression, 1031-1032
  - of mouse pancreas
    - and age related to streptozotocin damage, 719-720, 722
  - of neosidioblastotic pancreas, 123, 124-125
  - of pancreas islets
    - of new strain of genetically obese-hyperglycemic rats, 1047, 1049
    - of pancreatic specimens from infants of diabetic mothers, 271-273
    - of ratfish islet cells
      - in glucagon immunoreactivity study, 193-194
    - of thyroid glands of rats with insulin-dependent diabetes and lymphocytic thyroiditis, 1059
- MICROVASCULAR DISEASE**
- and insulin-dependent diabetes acetylator dimorphism in, 907-909
- MINERALS.** See Calcium; Potassium; Zinc
- MONKEYS**
- cultured arterial cells
    - insulin effects on, \*55-56
- MONOCYTES**
- insulin binding by
    - and insulin resistant non-insulin-dependent diabetics, 990-995
  - insulin binding in normal and disease states, 896-901
- MONONUCLEAR LEUKOCYTES**
- somatostatin and glucagon binding identification in humans, 127-131

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88	April, 271-365	July, 539-620
February, 89-174	May, 367-458	August, 621-704
March, 175-270	June, 459-538	September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

**MONTREAL**

prospective study of viral antibody titers and HLA antigens in juvenile diabetics from, 584-589

**MORTALITY**

from atherosclerosis in diabetics and nondiabetics, \*1  
cardiovascular  
and diabetes, \*50-52  
causes in diabetics and nondiabetics, 327  
and diabetes gene expression in mice, 1031  
and hypertension  
in insulin-dependent juvenile-onset diabetics, \*90-96  
and juvenile diabetes long-term study, 177  
and male lethal diabetes syndrome in CBA/Lt mice, 1035-1043  
and neonatal nesidioblastosis  
pancreatic somatostatin and, 122-125  
and pneumonia in diabetics  
pneumococcal immunization and, 119-121

**MUSCIMOL**

glucose-stimulated somatostatin and insulin release  
from isolated, perfused rat pancreas, 168-170

**MUSCLE**

arterial smooth cells  
growth in diabetics, \*4  
proliferation, and endothelial injury, \*3  
capillary basement membrane width  
in parents of children with type 1 diabetes, 475-479  
gastrocnemius  
enzyme activities related to body weight, fasting serum insulin, and glucose tolerance, 19-25  
and insulin stimulation of glucose metabolism, 1000-1006  
skeletal  
capillaries of, in diabetics, 326-333  
effects of pregnancy and sex steroids on metabolism in, 545-550  
of genetically obese-diabetic mice, glucose metabolism in, 211-217  
insulin binding and glucose uptake in different types of, 702-704  
ornithine decarboxylase regulation, in fed and starved diabetic rats, 678-683

**MYELIN**

peripheral nerve  
proteolysis in streptozotocin-diabetic rats, 292-294

**MYELOMA**

immunoglobulin G  
and adipocyte lipogenesis study, 1068-1071

**MYOCARDIAL INFARCTION**

and atherosclerosis, \*39

**MYO-INOSITOL**

concentrations in cultured rat islets  
effects on insulin content, synthesis, glucose-induced secretion, and incorporation of  $^3\text{H}$ -thymidine into DNA, 621-625  
and symptomatic polyneuropathy in diabetics  
comparison of clinical course and sequential electrophysiological test results, 139-147

**N****NAXALONE**

infusion during digested and undigested gluten meal in dogs  
plasma insulin and glucagon levels and, 363-364

**NEPHROPATHY**

in diabetic mice  
diet control and prevention of, 106-111

**NERVE GROWTH FACTOR**

rapid axonal transport in diabetic rats, 797-802

**NERVOUS SYSTEM**

central  
glucose requirements, 261  
energy metabolism in peripheral nerve axons and Schwann cells in alloxan diabetic rabbits, 967-974  
motor nerve conduction velocity and aldose reductase inhibition in diabetic neuropathy, 460-463  
peripheral nerve myelin  
abnormalities in streptozotocin-diabetic rats, 292-294  
rapid axonal transport of proteins in streptozotocin-diabetic rats, 797-802  
sympathetic  
insulin and glucose infusions and activities in normal man of, 219-225  
sympathoadrenal, in diabetic rats  
increased plasma dopamine- $\beta$ -hydroxylase and, 419-420

**NESIDIOBLASTOSIS**

neonatal  
decrease of pancreatic somatostatin in, 122-125

**NEUROPATHY, DIABETIC**

autonomic  
hormonal, metabolic, and cardiovascular responses to insulin-induced hypoglycemia in juvenile-onset diabetics with, 626-632  
and composite energy metabolism in peripheral nerve axons and Schwann cells in diabetic rabbits, 967-974  
peripheral  
clinical trial of Alrestatin in, 459-463  
and sciatic nerve retrograde transport of proteins  
in diabetic rats, 797-802  
symptomatic polyneuropathy  
and comparison of clinical course and sequential electrophysiological test results in therapeutic trials with myo-inositol, 139-147

**NEUTROPHIL IODINATION REACTION**

in diabetics, 258-259

**NICOTINAMIDE**

and streptozotocin-treated rats  
insulin release from islet tissue and adenomas of, 302-308

**NICOTINIC ACID**

-induced lowering of plasma free fatty acids  
and hypersomatostatinemia of insulin deficiency in dogs, 358-360

**NOREPINEPHRINE**

-induced lipolysis  
in isolated rat adipocytes, prostacyclin production during, 163-166  
and microvessels of streptozotocin-diabetic Syrian hamsters, 96  
responses to glucose and insulin infusion in normal man, 219-225

**NUCLEIC ACIDS. See also DNA**

antibodies  
in insulin-dependent diabetics and unaffected relatives, 873-874

**NUTRITION**

and continuous central venous insulin infusion waveform studies in juvenile diabetics, 712-716  
plasma somatostatin-like immunoreactivity before and after mixed meal, 883-885  
role of somatostatin in homeostasis and, 883-885

**O****OBESITY**

and atherosclerosis  
and diabetes, \*1

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

and diabetes gene expression in mice, 1029–1030  
 and diabetes in mice  
     and hormone regulation of glucose metabolism, 211–217  
 and effects of sucrose overfeeding on Na, K-ATPase-mediated potassium uptake in mice, 975–978  
 familial  
     and hyperinsulinism in adults and offspring, 14–17  
 and glucose utilization during glucose clamp studies, 829–834  
 and hypertension in diabetics  
     and endothelial injury, \*2  
 and hypertriglyceridemia  
     and insulin resistance and hyperinsulinemia, \*4–5  
 insulin resistance in, 151–155  
 and lipoprotein lipase  
     in diabetics and nondiabetics, \*86  
 in mice  
     effect on encephalomyocarditis virus-induced diabetes, 451–454  
 and new strain of diabetic rat, 1045–1049  
 and skeletal muscle related to glucose intolerance and insulin resistance, 19–25

**OLEATE**  
 -enrichment of Friend erythroleukemia cells media  
 effects on insulin receptors, 773–779

**OPHTHALMOSCOPY**  
 and clinical trial of aldose reductase inhibitor in diabetic neuropathy, 460

**ORGANOGENESIS**  
 in streptozotocin-diabetic rats  
 and prevention of congenital lumbo-sacral defects in offspring, 965–969

**ORNITHINE DECARBOXYLASE**  
 regulation in skeletal muscle of diabetic fed and starved rats, 678–683

**OUABAIN**  
 and renal insulin uptake, 930–933  
 and veratridine-induced glucagon and insulin secretion from rat pancreas, 448, 449

**OVARIECTOMY**  
 and expression of mutations at diabetic locus in female mice, 1037–1039

**OVARIES**  
 steroids  
 and expression of mutations at diabetic locus in male mice, 1035–1039

### OXIDATIVE SULFITOLYSIS of $^{125}\text{I}$ -insulin, 2

**6-OXO-PROSTAGLANDIN F<sub>1α</sub>**  
 production by rat aorta  
 and diabetes, insulin treatment, and caloric deprivation, 935–938

### OXYTOCIN

infusion in normal dogs  
 plasma insulin and glucagon levels and glucose production and uptake and, 112–114

### P

### PANCREAS. See also Artificial pancreas

A-, B-, and D-cell populations during postnatal development in rat, 813–817

abnormal beta-cell secretory product, 148–149

and basal plasma insulin and glucose concentrations in diabetic man, 435–439

B-cell function

vitamin D and, 382–385

B-cell microtubular structures and vincristine effect on glucose-induced insulin release from rat pancreas, 539–544

B-cell regeneration in streptozotocin-treated neonatal rats, 64–69

beta cells

immune lysis induced in mice, 30–38

bioartificial

in streptozotocin-diabetic rats, 296–301

D-cell

recognition of D-glucose, 203–209

dog islet cells

new method of preparation, 455–458

duct-ligated, subcutaneous isogenic transplantation in diabetic mice

glucose tolerance studies on, 857–863

fetal mouse

organ culture conditions effect on insulin and glucagon secretion, 804–811

fetal and neonatal rat

glucose-induced insulin secretion in, 56–62

glucagon

response to oral glucose in normal and gestational-diabetic pregnancy, 504–508

transformation of glucagon-like immunoreactivity of pig gut into, 792–794

glucagon and insulin content in mice

and streptozotocin and superoxide dismutase, 634–638  
 of infants of diabetic mothers  
 insulin, glucagon, somatostatin, and pancreatic polypeptide in, 271–273

insulin biosynthesis, 148  
 and insulin resistance, 148  
 islet allografts transplantation  
 cellular stimuli for rejection of, 242–246

donor strain ACI blood transfusions and ALS therapy and survival of, 947–950

islet cell antibodies from diabetics, alterations in insulin release in vitro by, 1051–1056

induced in mice, 30–38  
 islet cell intraportal transplantation in streptozotocin-diabetic rats

kidney hypertrophy and glomerular basement membrane accumulation after, 481–485

islet cell membrane electrical activity glucose and acetylcholine and, 558–561

islet histology and streptozotocin effects in mice, age and, 719–720, 722

islet mass and B-cell function loss preceding hyperglycemia in mice given multiple low doses of streptozotocin, 424–429

islet secretion studies in neonatal rat model for non-insulin-dependent diabetes, 590–594

islet tumor cells hormones and factors stimulating growth of, 1022–1027

islets of genetically obese and lean mice, encephalomyocarditis virus-induced diabetes and, 451–454

isolated perfused rat effect of muscimol on glucose-stimulated somatostatin and insulin release from, 168–170

glucose and cyclic AMP and somatostatin and insulin secretion in, 40–44

isolated rat islets age and proinsulin and insulin secretion from, 77–82

in bioartificial pancreas, 296–301 prostacyclin and 6-keto-prostaglandin F<sub>1α</sub> effects on insulin secretion and cyclic AMP content in, 824–827

mouse islets incubated with serum from diabetic patients with complement-fixing islet cell antibodies, 1051–1056

neonatal porcine and formation of pseudo islets, 580–583

### DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1–88  
 February, 89–174  
 March, 175–270

April, 271–365  
 May, 367–458  
 June, 459–538

July, 539–620  
 August, 621–704  
 September, 705–796

October, 797–889  
 November, 891–982  
 Supplement 2, 1–110  
 December, 983–1113

- neonatal rat**  
and prostaglandin E synthesis and insulin secretion, 551-556
- neonatal rat islets**  
streptozotocin and, 64-69
- newborn rat monolayer cultures**  
effects of veratridine and calcium on glucagon and insulin secretion from, 446-449
- rabbit beta cells**  
and triphenyltin fluoride-inhibition of insulin secretion, diabetic lipemia and, 1013-1020
- rat**  
effects of insulin and insulin secretagogues on calcium-dependent phosphatidylinositol breakdown and amylase secretion in, 396-401
- ethanol, acetaldehyde, and acetate effects on glucose-induced insulin and glucagon secretion in, 705-708
- vincristine and glucose- and arginine-induced insulin release and glucose tolerance in, 539-544
- rat fetal**  
transplantation into adult diabetic rats, 9-12
- rat islet B-cells**  
somatostatin mechanism of action in, 836-841
- rat islet cell membrane**  
monoclonal antibodies reacting with antigens of, 226-230
- rat islet cells**  
 $\beta$ -adrenergic binding sites in, 172-174  
antibodies and complement blockade of insulin release by, 231-234  
calcium content response to glucose in, 52-54  
glucose metabolism and glucokinase study, 923-928  
myo-inositol concentrations and insulin content, synthesis and secretion and incorporation of  $^3\text{H}$ -thymidine into DNA, 621-625  
regulation of glucose metabolism in, 911-921  
and 3-isobutyl-1-methyl-xanthine priming of insulin release in, 754-756  
from nicotinamide and streptozotocin-treated rats, glucose-induced insulin release from, 302-308  
and trifluoperazine inhibition of glucose-stimulated insulin release, 960-966  
zinc-induced inhibition of insulin secretion from, 341-344
- rat islet xenografts in mice**  
prolongation of survival of, 285-290
- ratfish islet cells populations**
- differing glucagon immunoreactivity of, 192-195**
- somatostatin**  
decrease in neonatal nesidioblastosis, 122-125
- somatostatin secretion abnormalities in diabetic rats**  
insulin therapy and, 865-867  
transplantation in streptozotocin-diabetic rats  
glomerular lesions and, 111  
reversal of increased gastric somatostatin release and, 724-726
- PANCREATECTOMY**  
in dogs  
and transplantation of islet cells prepared by new method, 456-458  
duodenal, gastrectomy and  
and glucagon immunoreactivity and somatostatin action, 851-855  
and effect of islet-activating protein in dogs, 433-434  
insulin requirements after, 641-642
- C-PEPTIDE**  
assays  
in continuous central venous insulin infusion study, 711  
and insulin and glucose response to glucagon injection  
in mild and severe diabetics and normal subjects, 685-692  
levels  
and exercise in normals and diabetics, 985  
urinary excretion  
correlation with insulin secretion in normal subjects, 639-642
- PERICYTES**  
degeneration in skeletal muscle capillaries of diabetics, 326-333
- PGI<sub>2</sub>**. See Prostacyclin
- pH**  
during recovery phase of diabetic ketoacidosis, 311, 312  
effect on insulin binding and action in cultured human fibroblasts, 402-405
- PHENFORMIN**  
toxicity  
and reduced hydroxylation of phenformin, 644-649
- PHENYLALANINE**  
release from skeletal muscle  
and insulin resistance in pregnancy, 549
- PHOSPHATIDYLINOSITOL**  
breakdown in rat pancreas  
insulin and insulin secretagogues and, 396-401
- PHOSPHODIESTERASE**  
cyclic AMP  
in adipose tissue from insulin-treated streptozotocin-diabetic rats, 372-375
- PHOSPHOFRUCTOKINASE**  
and ketoacidosis, 346-352
- 6-PHOSPHOFRUCTOKINASE**  
assay for fructose 2,6-bisphosphate in diabetic rat liver, 1062-1064
- PHOSPHORYLASE**  
in gastrocnemius muscle tissue  
fasting serum insulin and glucose tolerance and, 21-22, 24  
in skeletal muscle of genetically obese diabetic mice  
epinephrine and anoxia and, 214-215
- PHYSICS**  
and study of development of diabetic atherosclerosis, \*97-103
- PIG. See Swine**
- PIMA INDIANS**  
diabetic and nondiabetic  
and urinary excretion and renal clearance of specific plasma proteins, duration of diabetes and, 656-662  
obese glucose-intolerant and with normal glucose tolerance  
insulin resistance in, 744
- PITTSBURGH**  
insulin-dependent Diabetes Mellitus Registry, 279-283
- PITUITARY-ADRENAL AXIS**  
and idiopathic postabsorptive hypoglycemia, 465, 469
- PLACENTA**  
insulin binding studies, 196-201  
membranes  
binding studies with new insulin analogues, 519-520, 521
- PLASMA**  
acetaldehyde  
and chlorpropamide alcohol flush, 788-790  
alanine and lactate  
and hyperglucagonemia in dogs, 183-184

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88	April, 271-365	July, 539-620	October, 797-889
February, 89-174	May, 367-458	August, 621-704	November, 891-982
March, 175-270	June, 459-538	September, 705-796	Supplement 2, 1-110

---

**SUBJECT INDEX 1981**

albumin  
extravasation into cerebral cortex of streptozotocin-diabetic rats, 500–503  
-aqueous and -vitreous barriers in streptozotocin-diabetic rats, glucose transport across, 903–905  
cholesterol  
in diabetes, \*76, \*77  
dopamine- $\beta$ -hydroxylase activity in streptozotocin-diabetic rats, 416–423  
epinephrine and norepinephrine responses  
in insulin-induced hypoglycemia in diabetics with and without autonomic neuropathy, 628–629, 631  
factor VIII  
in diabetics, \*35–36  
free fatty acid levels  
and hypersomatostatinemia of insulin deficiency, 358–360  
gastrointestinal insulinotropic hormones response to oral glucose in normal and gestational-diabetic pregnancy, 504–508  
glucagon  
hepatic glucose production and, 490  
glucose  
and diagnosis of postprandial hypoglycemia, 996–999  
in dietary prevention of nephropathy in diabetic mice, 107  
and exercise in diabetics, 818–822  
and insulin infusion pump during diabetic pregnancy, 892–895  
in rural-urban diabetes prevalence study in Polynesians, 47–50  
and sodium 5-methoxysalicylate-enhanced intestinal insulin absorption in rats, 1065–1066  
in streptozotocin-diabetic rats with fetal pancreatic grafts, 10–11  
glucose, aceoacetate, beta-hydroxybutyrate, and acetone  
in diabetic ketoacidosis before and after partial rehydration, 510–517  
glucose, insulin, free fatty acids, and triglycerides  
in streptozotocin-diabetic rats, \*67–68  
glucose, insulin, and glucagon  
in streptozotocin-treated rats and normal rats, 189  
glucose, insulin, glucagon, glycerol, alanine, and lactate  
in insulinoma patients with hypoglycemia, 378  
glucose, insulin, and C-peptide response to glucagon injection in normal and diabetic subjects kinetic analysis of, 685–692

glucose concentration  
and activation of hormonal glucose counterregulatory systems, 262–263  
and glucose utilization and clearance in normal man, 535–537  
glucose determinations  
in mice, 90  
glucose levels  
and insulin therapy in type II insulin-resistant diabetics, 739–744  
after oral glucose tolerance tests and mixed meals in hypoglycemia patients, 465–469  
immunoreactive glucagon  
arginine stimulation of, in duodenopancreatectomized and gastrectomized human, 851–855  
immunoreactive glucagon components hepatic extraction in dogs of, 767–779  
immunoreactive insulin  
in diabetic and normal mice, 108, 110  
insulin  
and glucose counterregulation in man, 261–264  
response to glucose, atherosclerotic vascular disease risk and, \*58–59  
insulin and glucagon levels in dogs exorphins and, 362–364  
in glycogenolysis and gluconeogenesis study, 182  
oxytocin infusion and, 112–114  
insulin and glucose  
brief, irregular oscillations of basal concentrations in diabetics, 435–439  
and colchicine administration, 1008–1012  
insulin levels  
and insulin evaluation in diabetics, 650–655  
lipid and glucose levels  
of triphenyltin fluoride-treated rabbits, 1015–1016  
lipids  
dietary fat and cholesterol and, \*88 in insulin-dependent diabetics, 132–137  
lipoprotein composition  
triphenyltin fluoride and, 1017  
lipoproteins  
metabolism in atherosclerosis \*60–65  
norepinephrine  
and effect of insulin and glucose infusions on sympathetic nervous system activity in normal man, 219–225  
C-peptide, glucagon free fatty acids, and 3-hydroxybutyrate  
and exercise in diabetics and normals, 985–986  
phenformin levels  
and phenformin toxicity study, 644–649

proteins  
urinary excretion and renal clearance, diabetes duration and, 656–662  
removal of very-low-density lipoproteins in streptozotocin-diabetic rats, 496–499  
somatomedin C  
in children with insulin-dependent diabetes, effect of pubertal stage and blood glucose control on, 868–871  
somatostatin  
radioimmunoassay, 728–733  
somatostatin-like immunoreactivity measurement by radioimmunoassay after affinity chromatography, 471–474  
in study of somatostatin hormonal status in man, 883–885  
 $\beta$ -thromboglobulin and platelet factor 4 and coronary artery disease, peripheral artery disease, and diabetes, \*33–34  
triglyceride, cholesterol and lipoproteins  
in obese children of obese parents, 15–17  
very-low-density lipoproteins  
and high carbohydrate diet, 530–533

**PNEUMOCOCCAL IMMUNIZATION**  
in adult diabetics, 119–121

**POLYMORPHONUCLEAR LEUKOCYTES**  
from insulin-treated diabetics decreased stimulation of glucose oxidation and iodination by, 256–259

**POLYNESIANS**  
diabetes prevalence study rural-urban comparisons, 45–50

**POLYNEUROPATHY**  
symptomatic in diabetics and electrophysiological test results compared with clinical course, 139–147

**POLYOLS**  
accumulation in peripheral nerves and lens in diabetic and galactose-fed rats, 459

**POLYPEPTIDES**  
pancreatic  
in infants of diabetic mothers, 271–273

**POPULATION STUDIES**  
of atherosclerotic vascular disease risk and plasma insulin response to glucose, \*58–59  
of hyperglycemia as risk factor for atherosclerosis, \*50–52

---

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

January, 1–88  
February, 89–174  
March, 175–270

April, 271–365  
May, 367–458  
June, 459–538

July, 539–620  
August, 621–704  
September, 705–796

October, 797–889  
November, 891–982  
Supplement 2, 1–110  
December, 983–1113

- of insulin-dependent juvenile onset diabetics
- hypertension and mortality in, \*90-96
- and relationship between insulin levels and atherosclerosis, \*54-55
- PORTAL VEIN**
- transplantation of isolated rat islets into diabetic mice via, 285-290
- POTASSIUM**
- glucose and insulin infusions and cardiovascular effects of, 225
- Na, K-ATPase-mediated uptake and sucrose overfeeding in normal and genetically obese mice, 975-978
- permeability in islet B-cells somatostatin and, 836-841
- stimulated calcium uptake and insulin release and trifluoperazine, 961-962
- PREDNISONE**
- and insulin binding by erythrocytes and monocytes, 899
- PREGNANCY**
- in female rats with fetal pancreatic grafts, 10
- and hyperinsulinemia, 504
- and skeletal muscle metabolism in rats, 545-550
- PREGNANCY, DIABETIC**
- control during and prevention of congenital lumbosacral defects in rats during organogenesis, 965-969
- gestational and gastrointestinal insulinotropic hormones response to oral glucose, 504-508
- and immunocytochemical study of pancreatic specimens from infants, 271-273
- insulin infusion pump treatment in, 891-895
- PROCOLLAGEN**
- type 1 in arterial wall, growth hormone and, \*16
- PROGESTERONE**
- and expression of mutations at diabetic locus in male mice, 1036-1039
- and skeletal muscle metabolism in rats, 548-550
- PROINSULIN**
- incomplete conversion to insulin, 148
- secretion from isolated rat islets, age and, 77-82
- PROLACTIN**
- and rat islet tumor growth in serum-free medium, 1022-1027
- PROPERDIN FACTOR B ALLELES**
- and lymphocytotoxic antibodies in juvenile-onset diabetics, 27, 28
- PROPRANOLOL**
- epinephrine, glucose, and insulin infusions for measurement of insulin resistance in mildly diabetic or hyperlipidemic men cardiac arrhythmias during, 618-620
- PROSTACYCLIN**
- and insulin secretion and cyclic AMP content of rat isolated islets, 824-827
- production by endothelial cells from large and small vessels, \*26
- by isolated rat adipocytes, 163-166
- PROSTAGLANDIN E**
- release and colchicine inhibition of insulin secretion, 1008-1012
- synthesis in neonatal rat pancreas insulin secretion and, 551-556
- PROSTAGLANDIN ENDOPEROXIDES**
- synthesis by platelets, \*47
- PROSTAGLANDINS**
- in isolated rat adipocytes, 164
- PROTEASE INHIBITORS**
- in diabetes, \*36
- PROTEIN**
- and coagulation \*34-35
- /DNA ratio in kidneys of diabetic rats kidney cell size calculations and, 484, 485
- dietary peptides with opioid-like activity in peptic digests of, 362-364
- glycosylated in diabetics, 616
- islet-activating, see Islet-activating protein
- myelin proteolysis in streptozotocin-diabetic rats, 292-294
- rapid axonal transport in diabetic rats, 797-802
- urinary excretion and renal clearance diabetes duration and, 656-662
- PROTEIN ACTIVATOR**
- of cyclic AMP phosphodiesterase in adipose tissue of streptozotocin-diabetic insulin-treated rats, 372-375
- PROTEIN A-GOLD TECHNIQUE**
- and demonstration of glucagon in human fetal stomach, 879-882
- PROTEINURIA**
- in juvenile-onset, insulin-dependent diabetics, 178
- PROTEOGLYCANES**
- of cartilage and bone biosynthesis abnormalities in streptozotocin-diabetic rats, 670-677
- PROTEOLYSIS**
- of myelin proteins in streptozotocin-diabetic and normal rats, 292-294
- PROTEOSE PEPTONE**
- and rat islet tumor growth in serum-free medium, 1022-1027
- PROTHROMBIN**
- in diabetics, \*35
- PUBERTY**
- and plasma somatomedin C in insulin-dependent diabetic children, 868-871
- PYRUVATE DEHYDROGENASE**
- in skeletal muscle of genetically obese-diabetic mice insulin and, 216

**Q**

- QUININE**
- and electrophysiologic activity of somatostatin in islet B-cells, 837-841

**R**

- RABBITS**
- alloxan diabetic and energy metabolism in peripheral nerve axons and Schwann cells, 967-974
- aorta comparison of two types of reaction to arterial wall injury in, \*11-12
- mechanical injury and formation of atherosclerotic lesions, \*8-9
- and selective endothelial injury, \*10-11
- aorta myomedial cells growth

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88	April, 271-365	July, 539-620
February, 89-174	May, 367-458	August, 621-704
March, 175-270	June, 459-538	September, 705-796

October, 797-889
November, 891-982
Supplement 2, 1-110
December, 983-1113

- as model of diabetic macroangiopathy, \*14–16  
cholesterol-fed, alloxan-diabetic insulin deficiency and atherosclerosis incidence in, \*55  
endothelial injury and artery wall injury in, \*2–3  
triphenyltin fluoride-induced hypertriglyceridemia in, 1013–1020
- RACE**  
and atherosclerosis incidence in Japanese diabetics, \*1  
and insulin-dependent diabetes in Pittsburgh Registry, 280, 281, 283  
and urinary excretion and renal clearance of plasma proteins in Pima Indians and Caucasians, 656–662
- RADIOIMMUNOASSAYS**  
for human plasma somatostatin, 728–733  
for  $^{125}\text{I}$ -insulin, 2  
for lymphocyte hybrid cell antibodies, 227  
of pancreatic tissue from neonates with neosidoblastosis, 123, 124–125  
of somatostatin-like immunoreactivity in human peripheral plasma affinity chromatography prior to, 471–474
- RAT**  
adipocytes  
insulin-induced receptor loss and internalization in, 746–752  
adipocytes and hepatocytes  
 $^{125}\text{I}$ -insulin binding in, 4–5  
adipocytes and liver insulin receptors insulin binding studies, 196–201  
alloxan diabetic  
and hepatic fructose 2,6-bisphosphate levels, 1062–1064  
alloxan diabetic and fasted coagulation studies in, \*36–37  
aorta  
6-oxo-prostaglandin  $\text{F}_{1\alpha}$  production, diabetes, insulin, and caloric deprivation and, 935–938  
arterial smooth muscle cells  
insulin effects on lipid metabolism of, \*56–57  
cultured pancreatic islets  
*myo*-inositol concentration and glucose-induced insulin secretion and  $^3\text{H}$ -thymidine incorporation into DNA, 621–625  
diabetic  
intestinal glucose uptake in, 247–255  
diabetic and galactose-fed  
peripheral nerves and lens sorbitol and galactitol accumulation in, 459  
fed and starved  
and regulation of ornithine decarboxylase in skeletal muscle, 668–683  
fetal and neonatal  
glucose-induced insulin secretion in, 56–62  
fetal pancreas  
transplantation into adult diabetic rats, 9–12  
gastrointestinal insulin absorption and sodium 5-methoxysalicylate, 1065–1066  
genetically obese-hyperglycemic new Wistar fatty strain, 1045–1049  
glomerular basement membrane nonenzymatic glycosylation of, 367–370  
glucose- and arginine-induced insulin release and glucose tolerance in vincristine and, 539–544  
inhibition of superoxide dismutase by diabetogenic drugs in, 235–240  
islet allograft transplantation in cellular stimuli for rejection of, 242–246  
donor strain blood transfusions and ALS therapy and, 947–950  
islet B-cells  
somatostatin mechanism of action in, 836–841  
islet cell membrane antigens monoclonal antibodies reacting with, 226–230  
islet tumor cells  
hormones and factors stimulating growth of, 1022–1027  
islets  
and trifluoperazine inhibition of glucose-stimulated insulin release, 960–966  
transplantation into mice, prolongation of survival of, 285–290  
zinc-induced inhibition of insulin secretion from, 341–344  
isolated adipocytes  
prostacyclin production, 163–166  
isolated islets  
effect of age on proinsulin and insulin secretory patterns in, 77–82  
3-isobutyl-1-methyl-xanthine priming effect on insulin release, in, 754–756  
prostacyclin and 6-keto-prostaglandin  $\text{F}_{1\alpha}$  effects on insulin secretion and cyclic AMP content in, 824–827  
isolated, perfused pancreas  
effect of muscimol on glucose-stimulated somatostatin and insulin release from 168–170  
glucose and cyclic AMP stimulation of somatostatin and insulin secretion in 40–44
- neonatal pancreas  
and prostaglandin E synthesis and insulin secretion study in, 551–556  
neonatal pancreatic islets streptozotocin and, 64–69  
neonatal streptozotocin diabetes as model for non-insulin-dependent diabetes, islet secretion studies in, 590–594  
newborn pancreas monolayer cultures and effects of veratridine and calcium on glucagon and insulin secretion from, 446–449  
nicotinamide- and streptozotocin-treated islet tissues and adenomas from, glucose and insulin release studies in, 302–308  
pancreas  
effects of insulin and insulin secretagogues on calcium-dependent phosphatidylinositol breakdown and amylase secretion in, 396–401  
pancreatic islets  
calcium content response to glucose in, 52–54  
exposure to islet-cell-specific antibodies and complement, insulin release and, 231–234  
glucose metabolism, glucokinase and, 923–928  
preponderance of  $\beta$ -adrenergic binding sites in, 172–174  
regulation of glucose metabolism in, 911–921  
postnatal  
pancreatic islet development in, 813–817  
retina and erythrocytes superoxide dismutase and diabetogenic drugs, 235  
skeletal muscle metabolism  
effects of pregnancy and sex steroids on, 545–550  
spontaneous insulin-dependent diabetes  
and lymphocytic thyroiditis, 1058–1060  
spontaneously diabetic Wistar "BB" T-cell lymphocytopenia in, 887–889  
spontaneously obese, insulin resistant, and hyperinsulinemic streptozotocin and hypertriglyceridemia in, \*70–71  
streptozotocin-diabetic  
arterial wall lipid metabolism in, \*55  
bioartificial pancreas in, 296–301  
and cartilage and bone proteoglycans biosynthesis abnormalities in, 670–677  
cerebral edema following fluid and insulin therapy in, 762–766  
in cholesterol metabolism studies, \*79–81  
and cyclic AMP phosphodiesterase

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1–88	April, 271–365	July, 539–620	October, 797–889
February, 89–174	May, 367–458	August, 621–704	November, 891–982
March, 175–270	June, 459–538	September, 705–796	Supplement 2, 1–110
			December, 983–1113

and protein activator in adipose tissue from, 372-375  
 gastric somatostatin concentration and secretion in, 188-191  
 glucose transport across ocular barriers of, 903-905  
 hypertriglyceridemia in, \*66, \*67-68, \*69, \*70-71, \*72-74  
 and increase in arterial myomedial cells, \*15-16  
 iodothyronine metabolism in, 694-698  
 islet cell transplantation and kidney hypertrophy and glomerular basement membrane accumulation in, 481-485  
 pancreas transplantation effects on gastric somatostatin release in, 724-726  
 pancreatic somatostatin secretion abnormalities and insulin treatment in, 865-867  
 plasma dopamine- $\beta$ -hydroxylase activity in, 416-423  
 and plasma protein extravascular escape into cerebral cortex, 500-503  
 and plasma removal of very-low-density lipoproteins, 496-499  
 platelet aggregation and coagulation in pathogenesis of retinopathy in, 601-606  
 proteolysis of myelin proteins in, 292-294  
 retrograde transport of proteins in sciatic nerves of, 797-802  
 sugar transport in isolated small intestine from, 568-574  
 streptozotocin-diabetic pregnancy in and prevention of congenital lumbosacral defects in offspring, 965-969  
 vitamin D-deficient and effect of 1,25 dihydroxy-vitamin D<sub>3</sub> on insulin secretion in, 382-385

**RATFISH**

pancreatic islets differing glucagon immunoreactivity of islet cells of, 192-195

**RECOMBINANT DNA METHODOLOGY**  
and insulin synthesis, 265-266**RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM**

in diabetics with hyperkalemia, 335-339

**RESPIRATION**

exchange measurement and insulin clamp studies of glucose disposal, 100

**RETINOPATHY, DIABETIC**

and deterioration and closure of preexisting vessels \*24  
 in long-term study of juvenile-onset insulin-dependent diabetics, 177-178  
 platelet activation and plasma thromboxane B<sub>2</sub> in, \*42  
 and platelet release factors, \*34  
 in streptozotocin-diabetic rats platelet aggregation and coagulation in pathogenesis of, 601-606

**RIBOSE**

and somatostatin, insulin, and glucagon release, 207-209

**RISK FACTORS FOR ATHEROSCLEROSIS**

effects on platelets and vascular endothelium, \*39-42  
 and endothelial and smooth muscle cells in diabetics, \*41-42  
 and homocystinuria, \*40  
 and hyperlipidemia, \*40-41  
 and hypoxia, \*41  
 and high-density lipoproteins in diabetics, \*86  
 hyperglycemia, \*49-53  
 and hypertension in juvenile-onset insulin-dependent diabetics, \*90-96  
 plasma cholesterol levels and, \*76, \*78 and role of insulin in atherosclerosis, \*54, \*55

**RNA**

antibodies to  
 in insulin-dependent diabetics and unaffected relatives, 873-874  
 kidney content  
 in streptozotocin-diabetic rats, 484, 485

**S****SCATCHARD PLOTS**

in insulin binding studies, 199, 200  
 of <sup>125</sup>I-insulin binding to sheep erythrocytes, 412-414  
 of somatostatin and glucagon binding data from human mononuclear leukocytes, 128, 130

**SCIATIC NERVE**

rapid axonal transfer of proteins in streptozotocin-diabetic rats, 797-802

**SEMICARBAZIDE**

and removal of labile glycohemoglobin in hemoglobin A, assay, 700-701

**SERUM**

Alrestatin levels  
 in clinical trial of Alrestatin in diabetic neuropathy, 460, 462, 463  
 antiglucagon and antiglicentin and human fetal stomach glucagon, 879-882  
 anti-insulin  
 binding studies with new insulin analogues, 519, 520-521  
 antilymphocyte  
 and blood donor-specific pretreatment, pancreatic islet allograft survival in rats and, 947-950  
 in mice given multiple low doses of streptozotocin, 427-428  
 antiplatelet  
 and prevention of atherosclerosis in mechanically injured arteries, \*9  
 cholesterol, high density lipoproteins, and triglycerides  
 and hypertension as risk factor in insulin-dependent, juvenile-onset diabetics, \*94, \*96  
 diabetic  
 and PAS-positive fibronectin and collagen in arterial wall, \*16  
 from diabetic and nondiabetic rats  
 and ornithine decarboxylase regulation in rat skeletal muscle, 681-682, 683  
 from diabetic patients, soluble immune complexes from  
 platelet aggregation and ATP release after incubation with 575-578  
 from diabetic patients with complement-fixing islet-cell antibodies  
 and insulin release in vitro from isolated mouse islets incubated with, 1051-1056  
 electrolytes and organic acids  
 and hyperchloremic acidosis during recovery phase of diabetic ketoacidosis, 310-313  
 fibrinogen  
 in diabetics, atherosclerosis and, \*3  
 glucose  
 and prevention of lumbar and sacral malformations in offspring of streptozotocin-diabetic rats, 965-969  
 glucose responses and free insulin concentrations  
 and insulin-induced hypoglycemia in diabetics with and without autonomic neuropathy, 628, 631  
 glycosidase activity  
 in diabetics, 115-117  
 insulin  
 and adipocyte size, 19  
 and skeletal muscle morphology and enzyme activities, 19-25  
 and tumor development in nicotinamide- and streptozotocin-treated rats, 304

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
 February, 89-174  
 March, 175-270

April, 271-365  
 May, 367-458  
 June, 459-538

July, 539-620  
 August, 621-704  
 September, 705-796

October, 797-889  
 November, 891-982  
 Supplement 2, 1-110  
 December, 983-1113

lymphocytotoxic antibodies  
in sera from insulin-dependent juvenile-onset diabetics, 26-29  
nitrogenous compounds and electrolytes  
during rehydration in diabetic ketoacidosis, 514-515  
from patients with familial hypercholesterolemia, familial hypertriglyceridemia, and combined hyperlipidemia  
and endothelial cells, \*40-41  
potassium  
and hyperkalemia in diabetics, renin-angiotensin-aldosterone system and, 335-339  
unmeasured anion gap in metabolic acidosis, 781-783, 783-785

**SEX**

and cardiovascular disease mortality in normoglycemic, borderline diabetic, and diabetic men and women, \*50-52  
and coronary artery disease in diabetics, \*14  
and expression of spontaneous diabetes in mice, 1029-1030, 1035-1043  
and expression of mutations at diabetes locus in mice  
male lethal syndrome and, 1035-1043  
and hyperinsulinemia and atherosclerosis, \*5  
of hypoglycemia patients in postabsorptive hypoglycemia study, 466  
of insulin-dependent diabetics in Pittsburgh Registry, 280, 281, 283  
of insulin-resistant non-insulin dependent diabetics, 991  
and risk of occlusive vascular disease in diabetics, \*2  
in rural-urban diabetes prevalence study in Polynesians, 47, 48, 49  
and serum glycosidase activity in diabetics and normals, 116

**SHEEP**

erythrocyte insulin receptors  
disappearance during maturation, 411-414

**SKIN**

albumin deposition in dermal capillary basement membrane  
in insulin-dependent diabetics, 275-278  
cultured human fibroblasts  
effect of pH and 3-hydroxybutyrate on insulin binding and action in, 402-405  
from patients with maturity-onset diabetes of the young, insulin binding and action in, 940-945

cultured human fibroblasts from diabetics and nondiabetics  
insulin binding, internalization, and insulin receptor regulation in, 596-600  
insulin and glucose metabolism study of, 562-566  
photosensitive rash  
in aldose reductase inhibitor trial in diabetic neuropathy patients, 462, 463

**SMOKING**

and endothelial damage, \*2  
and hypertension as risk factor for atherosclerosis  
insulin-dependent juvenile-onset diabetes, \*94, \*96  
and hypoxia and atherosclerosis  
endothelial and smooth muscle cell function in low oxygen environment and, \*41  
serum insulin, glucose tolerance and muscle enzyme activity, 23

**SOCIOECONOMIC FACTORS**

in rural-urban diabetes prevalence study in Polynesian populations, 46

**SODIUM**

and insulin and glucagon secretion  
calcium and, 446-449

**SODIUM 5-METHOXY SALICYLATE**

and intestinal insulin absorption in rats, 1065-1066

**SODIUM-POTASSIUM PUMP**

-mediated potassium uptake in obese and normal mice  
sucrose overfeeding and, 975-978

**SODIUM SALICYLATE**

and inhibition of prostaglandin E synthesis in neonatal rat pancreatic cells  
and insulin secretion, 551-556

**SOMATOMEDIN-C**

binding to cultured lymphocytes  
inhibition by naturally occurring anti-receptor antibodies, 979-981  
in plasma of insulin-dependent diabetic children  
effects of pubertal stage and recent blood glucose control on, 868-871  
and rat islet tumor cell growth in serum-free medium, 1025

**SOMATOSTATIN**

antidiabetic action of  
in totally duodeno-pancreatectomized and gastrectomized humans, 851-855  
-binding mononuclear leukocytes in human blood, 127-131  
and flow rate and triglyceride levels of thoracic duct lymph  
in normal and vagotomized dogs, 440-444

gastric concentration and secretion of in streptozotocin-diabetic rats, 188-191

gastric content and release in streptozotocin-diabetic rats  
pancreas transplantation and, 724-726

and glucagon deficiency in dogs  
liver glucose production and, 490-494

glucose-stimulated release from isolated perfused rat pancreas  
muscimol and, 168-170

hormonal status in man, 883-885  
-like immunoreactivity in human peripheral plasma  
radioimmunoassay following affinity chromatography and measurement of, 471-474

mechanism of action

in rat islet B-cells, 836-841  
pancreatic decrease in neonatal neosidoblastosis, 122-125

in pancreatic specimens from infants of diabetic mothers, 271-273  
radioimmunoassay in human plasma, 728-733

release  
glucose-mediated, 203-209  
responses to theophylline, high glucose, and arginine

by islets from new animal model for non-insulin-dependent diabetes, 593, 594

secretion  
from isolated, perfused rat pancreas, glucose and cyclic AMP and, 40-44

secretion abnormalities in diabetic rats  
insulin therapy and, 865-867

splanchnic release  
and insulin, 735-738  
and plasma free fatty acids, 358-360

-suppression of insulin secretion  
portal vein hormone measurements and, 664-668

**SORBITOL**

accumulation in peripheral nerves and lens of diabetic rats, 459  
intracellular accumulation of endothelial injury in diabetics and, \*2

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

**SPINE**

lumbar and sacral malformations in offspring of streptozotocin-diabetic rats and diabetic control, 965-969

**SPLANCHNIC NERVE**

glucose production insulin and, 1000-1006 protein- and acid-induced somatostatin release in dogs insulin and, 735-738

**SPLEEN**

cells and rejection of islet allografts, 242-246, 289-290

**STARVATION**

and ornithine decarboxylase regulation in rat skeletal muscle, 678-683 and rat hepatic fructose 2,6-bisphosphate levels, 1062-1064 and wound healing in mice, 407-410

**STEROIDS.** See also Progesterone; Testosterone and skeletal muscle metabolism in rats, 548-550

**STEROL**

suppression by triglyceride-rich lipoproteins in contact-inhibited endothelial cells, \*21-22

**STEROL BALANCE TECHNIQUES**

in cholesterol metabolism studies in diabetes, \*76-81

**STOMACH**

gastric somatostatin concentration and secretion in streptozotocin-diabetic rats, 188-191 of human fetuses glucagon in, 879-882 of streptozotocin-diabetic rats reversal of increased gastric somatostatin by pancreas transplantation, 724-726

**STREPTOZOTOCIN**

diabetogenic effects in mice age and, 718-722 inhibition of islet superoxide, 235-240 multiple low doses in mice pancreas islet mass and B-cell function loss preceding hyperglycemia in, 424-429 neonatal rat islets responses to, 64-69 and nicotinamide-treated rats insulin release from islet tissues and adenomas of, 302-308

**STREPTOZOTOCIN DIABETES**

in mice effects of exogenous superoxide dismutase on, 634-638 and rat islet xenograft survival prolongation, 285-290 and subcutaneous, isogeneic transplants of duct-ligated pancreas, glucose tolerance studies in, 857-863 in neonatal rats and islet secretion studies as model for non-insulin-dependent diabetes, 590-594

in rats and adipose tissue cyclic AMP phosphodiesterase and protein activator, 372-375 anterograde and retrograde axonal transport of transmitter enzymes, fucose-labeled protein, and nerve growth factor in, 797-802 and bioartificial pancreas, 296-301 and cartilage and bone proteoglycans biosynthesis abnormalities, 670-677 and cerebral edema following fluid and insulin therapy, 762-766

in rats and cholesterol metabolism studies, \*78-81 and diabetic hypertriglyceridemia, \*66, \*67-68, \*69, \*70-71, \*72-74 and gastric somatostatin concentration and secretion, 188-191 and gastric somatostatin release, pancreas transplantation and, 724-726

and glomerular lesions, 111 and glucose transport across ocular barriers, 903-905 and increase in arterial myomedial cells, \*15-16 and increased plasma dopamine- $\beta$ -hydroxylase activity, 416-423 and intestinal glucose uptake, 247-255 and iodothyronine metabolism, 694-699 and kidney hypertrophy and glomerular basement membrane accumulation after islet cell transplantation, 481-485 and myelin protein proteolysis, 292-294 and 6-oxo-prostaglandin production by aorta, 935-938 pancreatic somatostatin secretion abnormalities and insulin treatment in, 865-867 plasma proteins extravascular escape into cerebral cortex of, 500-503 and plasma removal of very-low-den-

sity lipoproteins, 496-499 and platelet aggregation and coagulation in pathogenesis of retinopathy, 601-606 and prevention of congenital lumbo-sacral defects in offspring, 965-969 and sugar transport in isolated small intestine from, 568-574 and transplantation of fetal pancreas, 9-12 in Syrian hamsters and microvascular alterations, 93-100

**STROKE**

and atherosclerosis, \*39

**SUCINATE DEHYDROGENASE**

in gastrocnemius muscle tissue fasting serum insulin and glucose tolerance and, 21-22, 24

**SUCROSE**

overeating and Na, K-ATPase mediated potassium uptake in normal and obese mice, 975-978

**SUGARS**

and pancreas D-cell recognition of D-glucose, 203-209 transport in isolated small intestine of streptozotocin-diabetic rats, 568-574

**SULFONYLUREAS**

and blood platelet aggregation in diabetics, 488

**SUPEROXIDE DISMUTASE**

inhibition by diabetogenic drugs, 235-240 in mice with multiple low doses of streptozotocin, 634-638

**SURGERY.** See also Pancreatectomy duodeno-pancreatectomy and gastrectomy in humans glucagon immunoreactivity and anti-diabetic action of somatostatin in, 851-855 for implantation of peritoneal insulin infusion device, 1073 vagotomy in dogs and effect of somatostatin on thoracic duct lymph flow rate and triglyceride levels, 440-444

**SWINE**

miniature cholesterol-fed, anterior coronary arteries from, \*60, \*61

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88

April, 271-365

July, 539-620

October, 797-889

February, 89-174

May, 367-458

August, 621-704

November, 891-982

March, 175-270

June, 459-538

September, 705-796

Supplement 2, 1-110

December, 983-1113

- pancreas**  
pseudo-islets formed from single cell preparations of, 580-583
- Von Willebrands disease and resistance to atherosclerosis in, \*3
- SYRIAN HAMSTERS**  
streptozotocin-induced diabetes in and microvascular alterations, 93-100
- T**
- TEMPERATURE**  
of donor islets and prolongation of islet xenograft survival in mice, 285-290
- hyperglycemia and microangiopathy in cold-adapted eels, 317-325
- and insulin-induced receptor loss and internalization of insulin receptor in rat adipocytes, 747-752
- rectal in insulin-induced hypoglycemia in diabetics with and without autonomic neuropathy, 630, 631, 632
- TESTOSTERONE**  
and expression of mutations at diabetic locus in male mice, 1036-1039
- TETRADOTOXIN**  
and veratridine-induced glucagon and insulin secretion in rat pancreas, 447-448, 449
- THEOPHYLLINE**  
and glucose- and arginine-induced insulin secretion by islets from new animal model for non-insulin-dependent diabetes, 592-593, 594
- THIAZIDES**  
and hypertension therapy carbohydrate tolerance and, \*2
- THIOL**  
and iodotyronine metabolism in diabetic rats, 694-698
- THORACIC DUCT**  
lymph flow rate and triglyceride levels and somatostatin in normal and vagotomized dogs, 440-444
- THROMBIN-ANTITHROMBIN AXIS**  
and coagulation in diabetics, \*37
- THROMBOCYTOPENIA**  
induced in rabbits and antiplatelet serum, \*9
- β-THROMBOGLOBULIN**  
in plasma of coronary artery disease, peripheral artery disease and diabetes patients, \*33-34
- radioimmunoassay in platelet activation study in diabetics, \*42
- THROMBOSIS**  
coronary artery in acute myocardial infarction, \*39
- THROMBOXANE A<sub>2</sub>**  
and atherogenesis, \*3  
and coronary spasm, \*39  
in isolated rat adipocytes, 164  
synthesis and platelet arachidonic acid metabolism in diabetics, \*44-47
- <sup>3</sup>H-THYMIDINE**  
incorporation into DNA of rat pancreatic islets myo-inositol inhibition of, 622, 623-624
- THYROID GLANDS**  
and lymphocytic thyroiditis in insulin-dependent diabetic rats, 1058-1060
- THYROIDITIS**  
and diabetes, 1058-1060  
lymphocytic in diabetic rat, 1058-1060
- TISSUES**  
capillaries of eels and cold adaptation, 317-325  
differential inhibition of superoxide dismutase by diabetogenic drugs in, 235-240  
gastrocnemius muscle enzyme activities in relation to fasting serum insulin and glucose tolerance, 19-25  
insulin receptors differences in insulin binding characteristics, 196-201  
isolated rat adipocytes prostacyclin production, 163-166  
pancreatic and decrease of somatostatin in neonatal neosidioblastosis, 122-125  
from infants of diabetic mothers, histological studies of, 271-273  
from skeletal muscle capillaries of diabetics
- pericyte degeneration and basement membrane thickening, in, 326-333
- TRANSFERRIN**  
/immunoglobulin G clearance ratios as index for protein excretion, 658, 659, 661, 662  
and rat islet tumor growth in serum-free medium, 1022-1027
- TRANSPLANTATION**  
of fetal mouse pancreas into streptozotocin-diabetic mice in study of culture conditions and insulin and glucagon secretion, 806-811  
of islet allografts and rejection caused by contamination by passenger leucocytes, 242-246  
of islet allografts in rats donor strain blood transfusion and antilymphocyte serum and, 947-950  
islet cell in streptozotocin-diabetic rats and kidney hypertrophy and glomerular basement membrane accumulation, 481-485  
neonatal pig pseudo-islets as xenograft source for, 580  
pancreas and glomerular lesions in streptozotocin-diabetic rats, 111  
in streptozotocin-diabetic rats, reversal of increased gastric somatostatin release and, 724-726  
and prolongation of rat to mouse islet xenograft survival, 285-290  
of rat fetal pancreas into adult streptozotocin-diabetic rats, 9-12  
subcutaneous, isogenic duct-ligated pancreas in diabetic mice glucose tolerance studies in, 857-863
- TRIFLUOPERAZINE**  
and inhibition of insulin release, 960-966
- TRIGLYCERIDE**  
estimates in continuous central venous insulin infusion study, 711  
in plasma of obese children of obese parents, 15-17  
in thoracic duct lymph in normal and vagotomized dogs somatostatin and, 440-444
- TRIIODOTHYRONINE**  
and rat islet tumor growth in serum-free medium, 1022-1027

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88

February, 89-174

March, 175-270

April, 271-365

May, 367-458

June, 459-538

July, 539-620

August, 621-704

September, 705-796

October, 797-889

November, 891-982

Supplement 2, 1-110

December, 983-1113

**TRIPHENYLTIN FLUORIDE**

and hypertriglyceridemia in rabbits, 1013-1020

**TRYPSIN**

and proteolysis in peripheral nerve myelin  
in streptozotocin-diabetic and normal rats, 292-294

**TUMORS**

adenomas induced by nicotinamide and streptozotocin in rats  
insulin release from, 302-308  
insulinomas  
and insulin binding by erythrocytes and monocytes, 896-901  
and insulin suppression of hepatic glucose production and hypoglycemia in, 377-380  
rat islet  
hormones and factors stimulating growth of, 1022-1027

**TYROSINE A14 [<sup>125</sup>I]MONOIODOINSULIN.** See <sup>125</sup>I-Insulin**U****URIC ACID**

clearance  
and aldose reductase inhibition in diabetic neuropathy, 460

**URINE**

albumin excretion in response to exercise  
continuous subcutaneous insulin infusion in diabetic men and, 818-822  
electrolytes, organic acids, and net acid during recovery phase of diabetic ketoacidosis, 310-313  
excretion of nitrogenous compounds and rehydration during diabetic ketoacidosis, 510-517  
excretion of specific plasma proteins and diabetes duration, 656-662  
C-peptide excretion  
correlation with insulin secretion rates in normal subjects, 639-642  
samples  
in continuous central venous insulin infusion study, 711  
tests  
and aldose reductase inhibition in diabetic neuropathy, 460

volume and glucose excretion in streptozotocin-diabetic rats with fetal pancreatic grafts, 10

**V****VACOR**

inhibition of islet superoxide dismutase, 235-240

**VAGOTOMY**

in dogs  
and effect of somatostatin on thoracic duct lymph flow rate and triglyceride levels, 440-444

**VASCULAR DISEASE**

and decreased platelet survival in diabetics, \*33-34  
and juvenile-onset diabetics, 175-178  
peripheral  
in diabetics, \*49-50  
and prostaglandin endoperoxides synthesis, \*47

**VASCULAR SYSTEM**

cerebral and mesenteric vessels  
in genetically diabetic mice platelet aggregation studies in, 89-92  
microvascular alterations in streptozotocin-diabetic Syrian hamsters, 93-100

**VEINS**

hepatic and femoral catheterization techniques, and glucose disposal measurements, 1000-1006

**VERATRIDINE**

and glucagon and insulin secretion extracellular and intracellular calcium and, 446-449

**VINCERISTINE**

and glucose- and arginine-induced insulin release and glucose tolerance in rats  
mechanism of, 539-544

**VIRUSES**

Coxsackie B4  
and HLA antigen studies in juvenile diabetics and controls 584-589  
encephalomyocarditis-induced diabetes in mice

and effects of genetic obesity, 451-454

herpesvirus-induced atherosclerosis in chickens, \*29-31

**VITAMINS**

D deficiency in rats  
and effects of 1,25 dihydroxyvitamin D<sub>3</sub> on insulin secretion, 382-385

**VON WILLEBRAND'S DISEASE**

and resistance to atherosclerosis in pigs, \*3

**W****WATER**

brain content  
and plasma protein extravasation into cerebral cortex of diabetic rats, 502  
regional localization of cerebral edema following fluid and insulin therapy in diabetic rats, 762-766  
intake in diabetic and normal mice, 107  
unstirred intestinal layer in estimates of glucose kinetics, 247-255

**WEIBEL-PALADE BODIES**

in endothelial cells of large and small vessels, \*25-26

**WEIGHT. See Body weight****WHEAT GERM AGGLUTININ**

-induced insulin binding  
tissue differences in, 196-201

**WOUND HEALING**

as model of atherosclerosis, \*39-42  
in normal mice  
effects of antisera to insulin, 2-deoxyglucose-induced hyperglycemia, and starvation on, 407-410

**Z****ZINC**

-induced inhibition of insulin secretion from isolated rat islets of Langerhans, 341-344

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

January, 1-88

February, 89-174

March, 175-270

April, 271-365

May, 367-458

June, 459-538

July, 539-620

August, 621-704

September, 705-796

October, 797-889

November, 891-982

Supplement 2, 1-110

December, 983-1113

# Author Index

## A

- Abe, Hiromi, 188-191  
Abe, Ryuzo, 14-18  
Abraham, M., 664-669  
Ainuu, J., 45-51  
Albers, John J., 132-138  
Alberti, K.G.M.M., 650-655, 951-954  
Albisser, A. Michael, 710-717  
Almér, Lars-Olof, 788-791  
Altszuler, Norman, 112-114, 172-174, 903-906  
Anderson, Gunnar H., Jr., 335-340  
Anderson, Richard W., 996-999  
Ardila, Enrique, 101-105  
Aronoff, Stephen L., 656-663  
Arquilla, Edward R., 407-410  
Asbury, Arthur K., 139-147  
Assan, Roger, 296-301, 677, 1051-1057  
Avezzano, Eric S., 700-701  
Axelrod, Lloyd, 163-167

## B

- Baenziger, J., 875-878  
Banerji, Mary Ann, 310-313  
Barbosa, Jose, 873-874  
Bar-on, Hanoch, 496-499  
Baker, Lester, 965-969  
Baldwin, David, Jr., 979-982  
Bassett, David R., 618-620  
Bates, Susan E., 891-895  
Battistelli, F., 175-179  
Bauer, G.E., 302-309  
Bauman, William A., 265-266  
Bear, Robert A., 781-787  
Bell, Graeme, 267-270  
Belmonte, M.M., 584-589  
Bendayan, Moise, 317-325  
Bennett, Peter H., 402-406, 562-567, 656-663  
Bergström, Bengt, 788-791  
Berhanu, Paulos, 523-529  
Berman, Edwin L., 132-138  
Berner, Donna K., 911-922, 923-928  
Besse, J., 175-179  
Best, James D., 847-850  
Bhatheena, Sam J., 127-131  
Bianchi, Enrica, 685-693  
Billaud, L., 175-179  
Bilous, Rudolf W., 818-823  
Bishop, A.E., 122-126  
Blethen, Sandra L., 868-872  
Blix, P., 664-669  
Bloom, S.R., 122-126, 951-954  
Blumenthal, Stanley A., 335-340

- Bodansky, H.J., 907-910  
Boitard, Chr., 1051-1057  
Bolli, Geremia, 607-612  
Bonen, A., 702-704  
Bonner-Weir, S., 64-69, 590-595  
Bonnevieu-Nielsen, Vagn, 424-429  
Bosisio, E., 644-649  
Braunstein, Seth N., 139-147  
Braverman, Lewis E., 1058-1061  
Bressler, Rubin, 106-111  
Brimijoin, Stephen, 797-803  
Bringer, Jacques, 83-85, 851-856  
Britt, L.D., 580-583  
Brossa, Claudio, 685-693  
Brown, David M., 843-846  
Brown, Josiah, 9-13  
Brown, Judith A., 267-270  
Brown, Mark J., 139-147  
Brown, Thomas J., 773-780  
Brunetti, Paolo, 607-612  
Bruni, Bruno, 685-693  
Bryant, M.G., 122-126  
Bunker, Donna, 465-470  
Bunn, H. Franklin, 613-617  
Burch, Pamela Trueheart, 911-922, 923-928

- Burnett, M., 435-439  
Burr, Ian M., 857-864  
Buse, Maria G., 235-241

## C

- Carroll, Hugh J., 310-313  
Cartechini, María G., 607-612  
Caruso, G., 804-812  
Caruso, Joanne, 314-316  
Cerciello, Teresa, 1008-1012  
Chan, Timothy M., 211-218  
Chang, Albert, 393-395  
Charles, M. Arthur, 465-470  
Chavers, Blanche, 275-278  
Chen, Yili-der, I., 496-499  
Cherksey, Bruce, 172-174  
Cherrington, Alan D., 180-187, 490-495  
Cherry, Marianna, 30-39  
Chesa, P. Garin, 122-126  
Cheung, Marian C., 132-138  
Chiba, Tsutomu, 188-191, 724-727  
Chick, William L., 226-230, 1022-1028  
Chiara, Kazuo, 188-191, 724-727  
Christensen, N.J., 626-633  
Ciborowski, C. James, 367-371  
Ciconi, M., 644-649  
Clark, Samuel A., 382-386  
Claus, Thomas H., 1062-1064  
Clements, Rex S., 621-625

- Clore, E.T., 590-595  
Coggins, Julian T., 465-470  
Cohen, Howard L., 947-950  
Cohen, Margo P., 367-371  
Coleman, Douglas L., 1029-1034  
Colle, E., 584-589  
Collier, S., 804-812  
Colwell, J., 575-579  
Compagnucci, Pietry, 607-612  
Conover, Cheryl A., 678-684  
Cook, Daniel L., 558-561  
Coulston, G.L., 1068-1071  
Court, J., 26-29  
Coustau, Donald R., 891-895  
Craig, James W., 402-406  
Craighead, J.E., 451-454  
Crepeau, M.P., 584-589  
Crill, Wayne E., 558-561  
Crossley, J.R., 26-29  
Crouch, Rosalie K., 235-241  
Crump, T., 887-889  
Cryer, Philip E., 261-264  
Csáky, T.Z., 568-574  
Cudworth, A.G., 907-910

## D

- D'Alberto, Micaela, 685-693  
Dandona, P., 1068-1071  
D'Andrea, B.J., 451-454  
Davie, Joseph M., 242-246, 285-291  
DeBoer, W., 45-51  
Debray-Sachs, M., 1051-1057  
De Feo, Pierpaolo, 607-612  
DeFronzo, R.A., 1000-1007  
Dehayes, J.P., 211-218  
Delage, Anne, 101-105  
DeLuise, Mario, 975-978  
Deri, John J., 490-495  
Dhorajwala, J., 664-669  
Dilworth, Vickie, 940-946  
DiMaggio, Joseph, 903-906  
Dixit, P.K., 302-309  
Doberne, Leonard, 387-392, 829-835  
Dodson, Leonard E., Jr., 465-470  
Dollar, Laura A., 979-982  
D'Onofrio, Felice, 1008-1012  
Dons, Robert F., 896-902  
Drash, Allan L., 279-284  
Drury, P.L., 907-910

## E

- Eckel, Robert H., 132-138  
Egler, Joseph M., 965-969

## DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE

- |                  |                |                    |                     |
|------------------|----------------|--------------------|---------------------|
| January, 1-88    | April, 271-365 | July, 539-620      | October, 797-889    |
| February, 89-174 | May, 367-458   | August, 621-704    | November, 891-982   |
| March, 175-270   | June, 459-538  | September, 705-796 | Supplement 2, 1-110 |
|                  |                |                    | December, 983-1113  |

---

**AUTHOR INDEX 1981**

---

Ehrlich, Robert M., 710-717  
Eichner, Harvey, 465-470  
Eisenbarth, George S., 226-230, 887-889  
Elde, Robert P., 168-171  
Elliott, R.B., 26-29  
Ellis, Steven, 903-906  
El-Maghrabi, M. Raafat, 1062-1064  
El-Sabban, Farouk, 89-92  
Etzwiler, Donnell, 275-278  
Evans, D.A. Price, 907-910

**F**

Faaiuso, S., 45-51  
Farese, Robert V., 396-401  
Farrar, P., 875-878  
Felber, J.P., 1000-1007  
Felig, Philip, 891-895  
Field, J.B., 767-780  
Fielden, H., 951-954  
Fields, Rose M., 562-567  
Filler, Robert M., 710-717  
Finke, Edward H., 285-291  
Fischer, E., 568-574  
Fishbein, Howard A., 279-284  
Flier, Jeffrey S., 975-978  
Fong, Henry K.W., 1022-1028  
Franetzki, M., 1072-1075  
Frank, Harrison J.L., 757-761  
Freinkel, N., 56-63  
Frigo, I., 302-309  
Fujimoto, Wilfred Y., 446-450, 551-557  
Fujita, Takuo, 188-191, 724-727

**G**

Galbo, H., 626-633  
Galbraith, Gillian M.P., 235-241  
Galbraith, Richard A., 235-241  
Gamba, Silvia, 685-693  
Gandy, Samuel E., 235-241  
Ganguli, Supriya, 411-415  
Gavin, Laurence A., 694-699  
Gazdar, Adi, 226-230  
Geisen, K., 1072-1075  
Gelhrter, Thomas, 940-946  
Geller, David M., 416-423  
Genel, Myron, 891-895  
Geoffrey, W.G. Sharp, 52-55  
Gerber, Pietro P.G., 40-44, 865-867  
Gerich, John E., 296-301, 377-381, 535-537, 728-734, 990-995  
Ghafghazi, Taghi, 341-345  
Ginsberg, Barry H., 773-780  
Ginsberg, Henry, 739-745  
Ginsberg, Leonard C., 393-395  
Giugliano, Dario, 1008-1012  
Gliemann, Jørgen, 1-8  
Glóóth, Maria, 792-794  
Goff, D.V., 951-954

Gold, Gerald, 77-82, 634-638  
Goldman, Allen S., 965-969  
Goldstein, Marc B., 781-787  
Gonen, B., 875-878  
Gorden, Phillip, 896-902  
Gorn, Alan H., 670-677  
Goto, Yasuo, 188-191  
Gotheiner, Toby I., 929-934  
Götzsche, O., 481-485  
Gozes, Yehoshua, 314-316  
Greene, Douglas A., 139-147, 967-974  
Greene, K., 728-734  
Greenfield, Michael S., 387-392, 829-835  
Greider, M.H., 580-583  
Grill, V., 56-63  
Grodsky, Gerold M., 83-85, 634-638  
Grouse, Lynette H., 168-171  
Gundersen, H.J.G., 481-485  
Guttmann, R., 584-589

**H**

Haedt, L. Hallquist, 873-874  
Hagmüller, G., 1072-1075  
Halperin, Mitchell L., 781-787  
Halter, Jeffrey B., 847-850  
Hamburger, J., 1051-1057  
Hampshire, Jennifer, 112-114  
Handelman, D.J., 459-464  
Hannaford, Maureen C., 781-787  
Hansen, Bruno, 1-8  
Harris, Virginia, 358-361, 883-886  
Harrison, Len C., 354-357  
Haymond, Morey W., 377-381  
Haynes, B., 887-889  
Heaney, Thomas P., 824-828  
Heininger, Diane, 9-13  
Heldt, Anneliese, 83-85, 634-638  
Hellouin de Minibus, Cl., 175-179  
Hellsing, K., 19-25  
Henrichs, I., 362-364  
Hermansen, K., 203-210  
Hidaka, Hideki, 402-406, 562-567  
Higuchi Takeru, 1065-1067  
Hilstead, J., 626-633  
Hintz, Raymond L., 979-982  
Hiraiwa, Yoshiro, 440-445  
Hofeldt, Fred, 465-470  
Hoffman, L., 804-812  
Hoffman, Phyllis L., 326-334  
Holland, A., 362-364  
Holst, Jens J., 1-18  
Honey, R.N.M., 64-69  
Horaguchi, Atsushi, 455-458  
Hornes, Peter J., 504-509  
Howard, Barbara V., 358-361, 402-406, 562-567  
Huang, Shih-Wen, 873-874  
Hummel, Katharine P., 1029-1034  
Hyne, I., 584-589

**I**

Ideka, Hitoshi, 1045-1050  
Ikeuchi, M., 446-450  
Imamura, Toshinori, 440-445  
Imura, Hiroo, 471-474  
Irsigler, K., 1072-1075  
Ishibashi, Fukashi, 402-406, 562-567  
Ishibashi, Tatsuro, 601-606  
Ishida, T., 767-780  
Itoh, Mitsuyasu, 296-301, 728-734  
Iwasaki, Makoto, 519-522  
Iwatsuka, Hisahi, 1045-1050

**J**

Jackson, R., 887-889  
Jacobson, D., 875-878  
Jacot, E., 1000-1007  
Jakobsen, Johannes, 797-803  
Janah, S., 1068-1071  
Janic, Danilo, 960-966  
Jaspan, J.B., 664-669, 767-780  
Jenkins, D.J.A., 951-954  
Jequier, E., 1000-1007  
Jerntorp, Peter, 788-791  
Johnson, Eugene M., Jr., 416-423  
Johnson, R.L., 93-100  
Jones, Robert L., 486-489  
Joyner, W.L., 93-100

**K**

Kadowaki, Seizo, 188-191, 724-727  
Kalkhoff, Ronald K., 545-550  
Kanada, Akira, 1065-1067  
Kanatsuna, Takahiro, 231-234  
Kanazawa, Y., 446-450  
Kasuga, Masato, 354-357  
Kawato, Masanori, 440-445  
Kawazu, S., 446-450  
Keen, Harry, 818-823  
Kelso, John M., 407-410  
Kennedy, Allan Laurence, 115-118  
Khokher, M.A., 1068-1071  
Kienle, M. Galli, 644-649  
Kikuchi, M., 446-450  
Kilo, Charles, 326-334  
Kilpatrick, M., 575-579  
Kimsey, Gary, 235-241  
Klein, Jean-Claude, 101-105  
Klein, Steven H., 965-969  
Klier, M., 362-364  
Kobayashi, Masashi, 519-522  
Kondo, Motoharu, 430-434  
Kono, Norio, 346-353  
Korányi, L., 792-794  
Kosaka, K., 446-450  
Kosmakos, Frank C., 402-406  
Kowarski, A. Avinoam, 639-643  
Kraemer, F., 387-392  
Kramp, Robert C., 857-864

---

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

---

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

---

**AUTHOR INDEX 1981**

---

Krarup, T., 626-633  
Krausz, Yodphat, 960-966  
Kritz, H., 1072-1075  
Krentowski, Georges, 983-989  
Kühl, Claus, 504-509  
Kuller, Lewis H., 279-284  
Kuret, Jeffrey, 9-13  
Kurtz, A.B., 650-655  
Kuwajima, Masamichi, 346-353  
Kuzuya, Hideshi, 471-474

**L**

Lacroix, Marcel, 983-989  
Lacy, Paul E., 242-246, 285-291, 341-345  
Lacy, W.W., 180-187  
Laimins, M., 575-579  
Lake, W., 56-63  
Lampman, Richard M., 618-620  
Landsberg, Lewis, 219-225  
Lang, D.A., 435-439  
Lapolla, A., 705-709  
LaPorte, Ronald E., 279-284  
Larkins, Richard G., 256-260, 824-828, 939  
Lerner, Joseph, 402-406  
Larson, Ronald E., 396-401  
Lauritsen, Keld B., 504-509  
Lederman, Michael M., 119-121  
Lee, Stanley M., 106-111  
Lefebvre, Pierre J., 851-856, 983-989  
Leiter, Edward H., 30-39, 662, 1029-1034  
Lemaignen, Hervé, 101-105  
Leontire, Andrea, 923-928  
Lermark, Åke, 231-234, 424-429  
LeRoith, Derek, 70-76  
Lesniak, Maxine A., 70-76  
Lestrade, F., 175-179  
Lestrade, H., 175-179  
Levavasseur, F., 175-179  
Levine, Lawrence, 163-167  
Lev-Ran, Arye, 996-999  
Licht, J. Hamilton, 510-518  
Like, Arthur A., 1058-1061  
Linde, Susanne, 1-8  
Lindgärde, F., 19-25  
Lindgren, Frank T., 132-138  
Litell, H., 19-25  
Livingston, James N., 196-202  
Loria, Roger M., 89-92  
Louie, James, 127-131  
Lundqvist, G., 19-25  
Luyckx, Alfred, 851-856, 983-989

**M**

McConnell, Thomas J., 718-723  
McCorkle, Kay, 358-361  
McCuskey, Robert S., 500-503  
McDaniel, Michael L., 341-345

McDonald, Roderick, 940-946  
McEvoy, Robert C., 813-816  
Mackay, Wilma, 656-663  
Mackes, K., 728-734  
Mackintosh, David, 818-823  
MacLaren, Noel K., 718-723  
McLaughlin, Judith V., 718-723  
McMahon, Francis A., 694-699  
McPherson, Janet, 372-376  
Madsbad, S., 626-633  
Maeder, E., 1000-1007  
Manabe, Shigeo, 1013-1021  
Mandarino, Lawrence J., 377-381, 990-995  
Mandel, T.E., 804-812  
Manning, Michele, 634-638  
Marchal, Georges, 851-856  
Margolis, Simeon, 639-643  
Marinan, Barbara, 292-295  
Marks, James F., 475-480  
Marshall, Stephen, 746-753  
Maruhama, Yoshisuke, 14-18  
Matschinsky, Franz M., 911-922, 923-928  
Matsukura, Shigeru, 188-191, 724-727  
Matsuura, Takao, 1045-1050  
Matta, S.G., 302-309  
Matthews, D.R., 435-439  
Mayhan, W.G., 93-100  
Mehl, Thomas D., 115-118  
Meistas, Mary T., 639-643  
Meneghel, A., 705-709  
Merimee, Thomas J., 115-118  
Merrell, Ronald C., 455-458  
Metz, Stewart A., 551-557  
Michael, Alfred F., 275-278, 843-846  
Miles, John M., 377-381  
Miller, Max, 656-663  
Miller, Ralph E., 40-44  
Milne, B., 45-51  
Milner, R.D.G., 271-274  
Minaker, Kenneth L., 219-225  
Mirouze, Jacques, 851-856  
Misiewicz, J.J., 951-954  
Moeller, Marie, 694-699  
Molinari, M., 705-709  
Moosa, A.R., 664-669  
Morihara, Kazuyuki, 519-522  
Morosati, S., 644-649  
Mosora, Florentina, 983-989  
Moxley, Richard T., III, 106-202  
Mui, Mei Mei, 947-950  
Mullen, Yoko, 9-13

**N**

Nakabayashi, Hajime, 440-445  
Nakamura, Yoshio, 430-434  
Nakano, Koji, 430-434  
Nathan, David M., 700-701  
Neely, Philip, 1062-1064  
Negri, A., 644-649  
Nimni, Marcel E., 670-677  
Nishihata, Toshiaki, 1065-1067  
Nosadini, R., 650-655

Nowlain, Robert, 634-638  
Noy, G., 650-655  
Nozawa, Masumi, 724-727  
Nygaard, E., 19-25

---

**O**

Oh, Man S., 310-313  
Ongaku, Seiji, 519-522  
Öhlin, Hans, 788-791  
Oie, Herbert, 226-230  
Oka, Tatsushi, 519-522  
Olefsky, Jerrold M., 148-162, 523-529, 596-600, 746-753, 979-982  
Ong, Shu-Hui, 500-503  
Ono, Junko, 242-246  
Orchard, Trevor J., 279-284  
Orci, Lelio, 192-195, 879-882  
Österby, R., 481-485  
Owen, Oliver E., 510-518  
Overbach, David, 267-270

**P**

Pace, Caroline S., 621-625, 836-842  
Palazzolo, Marjorie, 372-376  
Paliakarakis, Nicolas, 983-989  
Pallotta, Johanna, 219-225  
Palmer, John L., 700-701  
Papoz, Laure, 101-105, 175-179  
Paradise, Caroline, 486-489  
Pardridge, William M., 757-761  
Passariello, Nicola, 1008-1012  
Patsch, Wolfgang, 530-534  
Perlman, Kusiel, 710-717  
Péterfy, F., 792-794  
Peterson, Charles M., 486-489  
Pettit, James R., 634-638  
Pfeiffer, E.F., 362-364  
Pham, Tan Chi, 851-856  
Phares, C.K., 93-100  
Phillips, Catherine, 30-39  
Pickup, John C., 818-823  
Pietri, Angel O., 883-886  
Pilkis, Simon J., 1062-1064  
Pirnay, Freddy, 983-989  
Poirier, R., 584-589  
Polak, J.M., 122-126  
Polonsky, K.S., 664-669, 767-780  
Porte, Daniel, Jr., 558-561, 847-850  
Pottick, Lorelle A., 196-202  
Pouplard, A., 1051-1057  
Poussier, Philippe, 296-301  
Prestele, K., 1072-1075  
Prince, Melvin J., 596-600  
Pugh, W., 664-669

**Q**

Qvist, Rajes, 256-260

---

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

---

January, 1-88  
February, 89-174  
March, 175-270

April, 271-365  
May, 367-458  
June, 459-538

July, 539-620  
August, 621-704  
September, 705-796

October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

---

**AUTHOR INDEX 1981**

---

**R**

- Rabkin, Ralph, 929-934  
Rasio, Eugenio, 317-325  
Raskin, Philip, 475-480  
Rassi, N., 887-889  
Ravazzola, Mariella, 192-195, 879-882  
Rayfield, Elliot J., 739-745  
Reach, Gérard, 296-301  
Reaven, E.P., 77-82  
Reaven, Gerald M., 77-82, 387-392, 496-499, 829-835  
Recant, Lillian, 127-131  
Redman, Robert S., 127-131  
Regis, Giorgio, 684-693  
Renold, Albert E., 40-44, 52-55, 865-867  
Ribes, Gerard, 52-55  
Rich, Stephen, 873-874  
Riley, William J., 718-723  
Rizza, Robert A., 377-381, 535-537, 990-995  
Robbins, Mark S., 168-171  
Robertson, R. Paul, 551-557  
Rodman, Harvey M., 119-121  
Rogers, Susan P., 935-939  
Röjdmark, S., 767-780  
Rosenbloom, Arlan, 115-118  
Rosenblum, William I., 89-92  
Rosenfeld, Ron G., 979-982  
Roth, Jesse, 70-78  
Rouiller, Dominique, 735-738  
Rowe, John W., 219-225  
Rozovski, S. Jaime, 578-684  
Rubenstein, Arthur H., 231-234, 767-780, 979-982  
Ruderman, Neil B., 678-684  
Rudolf, Mary C.J., 891-895  
Rushakoff, Robert J., 545-550  
Rushforth, Norman, 656-663  
Rutter, William J., 267-270  
Ryan, Janice, 896-902  
Rytting, J. Howard, 1065-1067

**S**

- Sabir, Mohammad A., 396-401  
Sacca, Luigi, 1008-1012  
Sagara, Hosaku, 440-445  
Sagel, J., 575-579  
Sai, P., 1051-1057  
Sakato, Shunichi, 440-445  
Sakurai, Hideo, 471-474  
Saltin, B., 19-25  
Santeusanio, Fausto, 607-612  
Santiago, Julio V., 868-872  
Santinga, John T., 618-620  
Sapir, Daniel G., 510-518  
Sar, Madhabananda, 382-386  
Sarantis, Kosmas, 1058-1061  
Sargeant, Daniel T., 868-872  
Sarson, D.L., 951-954  
Sato, Gordon H., 1022-1028

- Sausse, André, 296-301  
Savage, Peter J., 618-620  
Searce, Richard M., 226-230  
Scharp, C.R., 580-583  
Scharp, D.W., 580-583  
Schechter, Geraldine P., 127-131  
Schiffman, Gerald, 119-121  
Schmidt, Robert E., 416-423  
Schneider, Barbara B., 279  
Schnider, Stuart, 656-663  
Schonfeld, Gustav, 530-534, 875-878  
Schorry, Elizabeth, 940-946  
Schultz, Julie A., 226-230  
Schulz, Bernd, 829-835  
Schusdziarra, Volker, 362-364, 735-738  
Schwartz, Stanley S., 139-147  
Segre, Giorgio, 685-693  
Seino, Susumu, 471-474  
Seino, Yasuo, 188-191  
Seino, Yutaka, 471-474, 724-727  
Selawry, Helena P., 947-950  
Serjeantson, S., 26-29  
Service, F. John, 377-381  
Sessa, A., 644-649  
Sestoft, L., 626-633  
Seta, Takashi, 440-445  
Sgambato, Saverio, 1008-1012  
Shackelford, Annelie, 465-470  
Shah, Jayendra H., 539-544  
Sharp, Geoffrey W.G., 754-756, 960-966  
Sherwin, Robert S., 891-895  
Shigeta, Yukio, 519-522  
Shino, Akio, 71, 1072-1075  
Shows, Thomas B., 267-270  
Shulman, G.I., 180-187  
Sidenius, Per, 797-803  
Siegel, Eberhard G., 52-55  
Siegre, Eberhard G., 960-966  
Silberlicht, Ira, 292-295  
Simon, Douglas, 30-39  
Simon, Ido, 773-780  
Singh, Harbhajan, 292-295  
Sinha, Madhur K., 411-415  
Sirtori, C.R., 644-649  
Skau, Kenneth, 797-803  
Slama, Gérard, 101-105  
Smeltzer, James, 656-663  
Smoake, Al, 372-376  
Solomon, Solomon S., 372-376  
Sonne, Ole, 1-8  
Sorensen, Bonita J., 539-544  
Sorenson, Robert L., 168-171  
Spector, Arthur A., 773-780  
Sperling, Mark A., 411-415  
Spritz, Norton, 292-295  
Stastny, Peter, 475-480  
Stauber, William T., 500-503  
Stefan, Yolande, 192-195  
Steffes, Michael W., 424-429  
Steiner, Donald F., 231-234  
Steiner, Kurt E., 490-495  
Sternthal, Elliot, 1058-1061  
Stevens, Arthur L., 219-225  
Stevens, Bernard, 539-544

- Stojeba, P.C. 580-583  
Streeten, David H.P., 335-340  
Strom, Terry B., 314-316  
Stumpf, Walter E., 382-386  
Sunderlin, Frederick S., Jr., 335-340  
Surma, Maria, 367-371  
Suzuki, Ziro, G71  
Szabó, J., 792-794

**T**

- Taborsky, Gerald J., Jr., 847-850  
Takeda, Ryoyu, 440-445  
Tamai, Irene Y., 407-410  
Tamás, Gy., Jr., 792-794  
Tamborlane, William V., 891-895  
Taminato, Tomohiko, 188-191, 724-727  
Tan, M.H., 702-704  
Tanaka, Kenzo, 601-606  
Tanigawa, Keiichiro, 471-474  
Taniguchi, Yoshiaki, 601-606  
Tarui, Seiichiro, 346-353  
Tarvin, John T., 836-842  
Taylor, G., 718-723  
Taylor, R.H., 951-954  
Tchobroutsky, Georges, 101-105  
Tchou, Pat, 656-663  
Theophilus, J., 26-29  
Thomas, D., 584-589  
Thomson, A.B.R., 247-255  
Thurow, H., 1072-1075  
Tiengo, A., 705-709  
Tilton, Ronald G., 326-334  
Timson, C.M., 122-126  
Tingle, A., 584-589  
Tobey, T., 387-392  
Torella, Roberto, 1008-1012  
Tornheim, Patricia A., 762-766  
Török, Angela, 792-794  
Trent, D.F., 64-69  
Tric, Ph., 175-179  
Trimble, Elisabeth R., 40-44, 865-867  
Tronier, B., 626-633  
Trus, Michael D., 911-922, 923-928  
Tsai, Phoebe, 596-600  
Tsai, Tan-Sheng, 929-934  
Tsanakaws, J., 271-274  
Tsuda, Kinsuke, 471-474  
Turco, Gianluigi, 685-693  
Turner, R.C., 435-439  
Turtle, J.R., 459-464

**U**

- Unger, Roger H., 358-361, 735-738, 879-882, 883-886  
Urdanivia, Enrique, 367-371  
Usher, Patricia, 975-978  
Usukura, Noromi, 440-445

---

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

---

- January, 1-88  
February, 89-174  
March, 175-270  
April, 271-365  
May, 367-458  
June, 459-538  
July, 539-620  
August, 621-704  
September, 705-796

- October, 797-889  
November, 891-982  
Supplement 2, 1-110  
December, 983-1113

---

**AUTHOR INDEX 1981**

---

**V**

- Valerio, A., 705-709  
Valka, Beth, 940-946  
Van Obberghen, Emmanuel, 354-357  
Van Zile, J., 575-579  
Verdonk, Carlos A., 377-381, 535-537  
Vessby, B., 19-25  
Viberti, Giancarlo, 818-823  
Virella, G., 575-579

**W**

- Wachslicht-Rodbard, Helena, 896-902  
Wada, Osamu, 1013-1021  
Wagener, Diane K., 279-284  
Wahl, Larry, 127-131  
Wahl, Patricia W., 132-138  
Wahren, J., 1000-1007

- Waldeck, Nancy, 465-470  
Wasada, Taro, 358-361  
Watson-Wright, W.M., 702-704  
Weill, Victoria A., 911-922  
Weir, G.C., 64-69, 590-595  
Weiss, Roy E., 670-677  
Wells, David, 797-803  
Weringer, Eldora J., 407-410  
West, R., 584-589  
Whitehouse, S., 45-51  
Whitlow, Margaret G., 868-872  
Wiedenkeller, Dayna E., 754-756  
Wilkins, J., 584-589  
Williams, Phillip E., 180-187, 490-495  
Williamson, Joseph R., 326-334  
Wilson, G.L., 451-454  
Winegrad, Albert I., 139-147, 967-974  
Wirdnam, P.K., 271-274  
Wollheim, Claes B., 40-44, 52-55, 960-966  
Wyse, Beatrice M., 393-395

**Y**

- Yalow, Rosalyn S., 265-266  
Yamada, Kenneth M., 354-357  
Yanase, Eimei, 440-445  
Yoshida, Toshihide, 430-434  
Yoshimitsu, Kohei, 440-445  
Young, James B., 219-225  
Younoszai, R., 302-309
- 
- Z
- Zadik, Zvi, 639-643  
Zadunaisky, José A., 172-174, 903-906  
Zawalich, Kathleen C., 923-928  
Zawalich, Walter S., 911-922  
Zimmet, P., 26-29, 45-51  
Zitron, Ian M. 242-246  
Zmachinski, C.J., 590-595  
Zyznar, Edward S., 883-886

---

**DIABETES: VOLUME 30 (1981) PAGE NUMBERS BY ISSUE**

---

January, 1-88	April, 271-365	July, 539-620	October, 797-889
February, 89-174	May, 367-458	August, 621-704	November, 891-982
March, 175-270	June, 459-538	September, 705-796	Supplement 2, 1-110 December, 983-1113